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Clinically, Alzheimer’s Disease (AD) presents with cognitive dysfunction, cell death, 
and amyloid-beta (Aβ) plaque and neurofibrillary tangle (NFT) formation.  Moreover, 
age and gender are primary risk factors; women are at much higher risk for 
developing AD compared to men. Estrogens may be neuroprotective; however, 
clinical use in hormone replacement therapy (HRT) is controversial due to potential 
adverse effects. Experiments were conducted using the APPswe/PS1dE9 (DTG) and 
APPswe/PS1M146V/TauP301L (3xTgAD) transgenic mouse models to assess the 
efficacy of an estrogen pro-drug, estradiol-quinol (E2Q). Treatment groups consisted 
of vehicle, estradiol (E2), or E2Q in intact and ovariectomized (OVX) DTG females, 
intact DTG males, and intact 3xTgAD females and males.  The objectives of this 
study were to 1) characterize AD progression in a double transgenic (DTG) murine 
model and compare the efficacy of treatment with estradiol (E2) or E2Q in 
ovariectomized (OVX) and intact females, 2) compare the effects of E2Q in males, 3) 
  
determine if E2Q affects neurodegenerative disease progression in the triple 
transgenic (3xTgAD) murine model in both males and females, and 4) assess the 
effects of the neurodegenerative disease progression on mitochondrial function and 
determine if E2Q affects these endpoints.  E2Q did not stimulate uterine tissue and 
proved to be an effective intervention; treated DTG mice had better cognitive 
behavior, decreased amyloid precursor protein (APP), and amyloid beta (Aβ) protein 
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Chapter 1: Introduction 
Introduction  
 Alzheimer’s disease (AD) is a progressive neurodegenerative disease 
impacting 5.2 million Americans that are 65 years of age and older. In the next 40 
years the prevalence of AD in the American population is expected to more than 
double from 5.2 million in 2010 to 13.2 million in 2050 (Alzheimer’s Association 
2012). The recent surge of diagnoses is associated in large part with the aging baby 
boomer population who will all be 65 years or older by 2029. Alzheimer’s disease 
(AD) primarily affects women, with 3.4 million women affected compared to 1.8 
million men. Accordingly the role of decreasing gonadal steroids, particularly 
estradiol (E2) has been suspect as a critical factor in the onset and progression of AD. 
Studies have focused on the role of estradiol (E2) neuroprotection and mitochondrial 
deficiencies related to AD. This review will survey pertinent literature on the 
potential role of estrogen as a neuroprotective hormone, mitochondrial deficiencies 
associated with AD, and efficacy of Estradiol-Quinol (E2Q) as a potential therapeutic 
for AD.  
 
Alzheimer’s Disease 
Chronology of Alzheimer’s Disease in Humans Clinically, AD presents initially with 
evidence of cognitive impairment. As the neurodegenerative disease progresses, there 
is atrophy of the hippocampal formation, a decreased number of neuronal cell bodies, 
and formation of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) 
(Walsh and Selkoe 2004). While age is the leading risk factor for the development of 
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AD, genetic mutations as in the case of Familial Alzheimer’s Disease (FAD), can 
increase the chance of developing the disease. Multiple genetic variants have been 
identified in contributing to AD pathology, such as mutations in the amyloid 
precursor protein (APP), the γ-secretase enzymes (presenilin1 and 2), and the Tau 
protein. These genetic variants are commonly used in transgenic mouse models to 
study AD neuropathology and potential interventions.  
 
Amyloid Precursor Protein Production of amyloid-beta (Aβ), the plaque forming 
protein, develops from cleavage and breakdown of the amyloid precursor protein 
(APP).  APP is a transmembrane protein, proteolytically cleaved by the β-secretase 
enzyme producing the soluble APPβ fragment and the β-stub. The β-stub is cleaved 
by the gamma secretase enzyme complex to produce Aβ40 or Aβ42 and the APP 
intracellular domain (AICD; Figure 1). Alternatively α-secretase can also cleave full 
length APP generating the soluble APPα fragment and the α-stub. The α stub can be 
cleaved to produce the P3 fragment (LaFerla 2002, Figure 1). The Aβ fragments have 
been studied extensively due to the key role of the Aβ42 isoform in formation of 
plaques (Roher 1993). The Aβ42 isoform has hydrophobicity, allowing for quicker 
oligomerization, aggregation, and plaque formation (Saito 2011). While various Aβ 
fragment isoforms have been identified, recent identification of a third isoform, the 
Aβ43 isoform was found as frequently as Aβ42 variant in AD patients. The 
importance of this additional isoform solicits questions regarding isoforms and their 




Presenilin Enzymes Three main secretase enzymes, α, β, and γ-secretase (Figure 1) 
play a role in AD.  The secretase enzymes cleave APP at various points resulting in 
numerous fragment products. The α-secretases (ADAM 17, 10 and 9) form 
sAPPalpha and α-fragments while the β-secretase (BACE1) form APPsβ (N-terminal) 
and β-fragments (C-terminal) (Vetrivel 2007, Figure 1). α- and β-secretase compete 
equally for the APP substrate and therefore mutations that alter their activity can 
impact AD pathology.  The γ-secretase is a complex of proteins that work together to 
break up proteins by cleaving the C terminal fragments after the alpha and beta 
secretase have cleaved APP. Gamma secretase cleavage results in p3 (cleavage of α-
fragments) or in Aβ cleavage, which occurs between 40-41 or 42-43 (cleavage of the 
β -fragment)(Figure 1). Presenilin enzymes of the γ-secretase complex include 
presenilin 1 (PSEN1/PS1) and presenilin 2 (PSEN2/PS2).  Both are membrane 
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proteins that function as the catalytic subunit of the γ-secretase complex (Vetrivel 
2007).  FAD mutations in PS1 or PS2 selectively elevate levels of Aβ42 (Sherrington 
1996). These mutations are autosomal dominant and cause the most aggressive forms 
of AD, beginning as early as 30 years of age.  Variations of this enzyme have been 
investigated, using mouse models to alter the levels of amyloid fragments produced 
(Oddo 2003, Jankowsky 2004).  
 
Tau Protein Tau protein is a microtubule-associated protein (MAP), which upon 
hyperphosphorylation, aggregates forming neurofibrillary tangles (NFTs). There are 
various sites at which tau can be phosphorylated; regulated by a balance between tau 
kinase and phosphatase activity (Martin 2012). Glycogen synthase kinase-3 (GSK3), 
cyclin-dependent kinase-5 (CDK5), and mitogen-activated protein kinases (MAPK) 
have been considered as potential therapeutic targets for AD due to their role in tau 
phosphorylation (Martin 2012). As with the other AD associated proteins, there is 
also a tau mutation (TauP301L), which contributes to increased hyperphosphorylation 
of tau leading to a higher incidence of NFTs especially in the presence of Aβ (Götz 
2001, Oddo 2003).  In an adult population of AD patients, CSF tau concentrations 
significantly increased as compared to healthy, non-symptomatic patients (Tapiola 
2000). Measurement of the phosphorylated tau (p-tau) levels in combination with 
CSF Aβ concentrations provides a potential diagnostic tool for AD, which was more 
predictive than the presence of the apoE e4 allele (APOE4) alone (Buerger 2002). 
This correlation indicates the important role tau plays in AD pathology, thereby 
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suggesting the use of CSF p-tau levels as a sensitive measure of tau pathology 
(Buerger 2002).  
 The role of tau versus Aβ in the progressive pathology of AD is a question of 
balance and synergy; specifically, do these processes interact and occur together 
temporally?  In human subjects, Aβ production and accumulation occurs at the same 
time as tau hyperphosphorylation and aggregation. Vossel (2010) reported no changes 
in total Tau were observed after injection of Aβ 1-42 by lentivirus, with a significant 
increase in Tau phosphorylation at the Ser-396, Thr-231, and Ser-199/202 sites. 
These data suggest that Aβ may not directly increase Tau protein levels; rather it 
promotes phosphorylation of Tau thereby allowing for the hyperphosphorylated form 
of Tau to form and aggregate into tangles. Tau protein is a component of the AD 
pathology that appears to work with Aβ to instigate neuronal deficiencies (Vossel 
2010).  
 
AD Models With the high visibility of AD research many models have been 
developed to study the pathology of the disease. Models including cellular 
(Thinakaran 1996, Wang 2006), mouse (Oddo 2003, Jankowsky 2004, Lord 2006), 
and canine (Martin 2011, Dowling 2012) have been established. While all of these 
models allow for examination of the disease, they each have their own strengths and 
weaknesses. The cellular model is easily manipulated but too far removed from 
human systems to provide sufficient systemic answers. Transgenic mice provide an 
excellent investigational tool, but they can be difficult to assess behaviorally, 
particularly for AD associated cognitive decline. Accordingly, investigators have 
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developed a number of behavioral tests that take advantage of a spectrum of 
transgenic mouse models with AD pathology. The Swedish amyloid precursor protein 
chimeric mouse/human variant (APPSWE) and the exon-9-deleted variant of the 
human γ-secretase presenilin1 (PS1dE9) were used to generate the APP/PS1 double 
transgenic mouse model (Jankowsky 2004). The APPSWE variant, identified in a 
Swedish familial AD (FAD) case has two point mutations, K594N/M595L3, within 
the APP sequence, and the PS1dE9 variant is missing exon 9 within the presenilin1 
sequence. The APPSWE variant was also used to create the triple transgenic mouse 
model containing the APPSWE variant, the PS1 (PS1M146V) variant, and a Tau 
(TauP301L) variant (Oddo 2003).  
 
Alzheimer’s Disease and Estrogens 
Estrogen Neuroprotection Estrogens provide various routes of neuroprotection 
including direct estrogen receptor activation of the mitogen activated protein 
kinase/extracellular signal-related kinase (MAPK/ERK) pathway and non-receptor 
mediated antioxidant activity (Brinton 2001; Simpkins 2012). This antioxidant 
characteristic is due to the free phenolic hydroxyl group found on the A-ring of 
estradiol (Badeau 2005). Estrogen treatment has shown to up-regulate genes 
associated with neuronal survival such as bcl-2(+), IGFBP-5(+), Calmodulin(+), 
CaMKIIα(+), Mef2C(+), Connexin43(-), and Jak1 and 2(+ and -)(Manthey and Behl 
2006). Additionally, Manthey and Behl (2006) identified that ERα and β receptor 
transfected cells can positively and negatively regulate genes affiliated with AD such 
as APP(-), PS1(+ and -), and ADAM10(+). This suggests not only a potential effect of 
 7 
 
estrogen on APP at the gene level but also reveals a role specific receptor subtypes 
may play in altering gene expression. While estradiol (E2) is the key hormone 
examined regarding estrogen neuroprotection, recent evidence demonstrated that 
estriol (E3), which is less biologically active than estradiol, also inhibited Aβ 
oligomer formation in vitro (Morinaga 2011). This suggests that other estrogens may 
play a role in neuroprotection. Additionally, estradiol treatment following surgical 
menopause prevented memory deficits (Phillips and Sherwin 1992). As suggested by 
Resnick and colleagues (1997), there appears to be a critical time period for efficacy 
when using hormone replacement therapy (HRT); women who started HRT 1 year 
post- menopause did not regain their memory capacity, while women who started 
HRT at menopause retained their memory capacity (Resnick 1997). Temporal studies 
must be conducted to determine optimal timing for any hormonal treatments. Based 
on this and other research, estrogenic compounds are potentially viable therapeutic 
candidates for AD associated deficits as well as for menopause related symptoms.  
 
Androgens and Progesterone While many studies focus on estrogens, other hormones 
such as progesterone and androgen have also shown promise in ameliorating AD 
related pathologies. Progesterone has been shown to protect against a variety of 
excitotoxic insults such as glutamate toxicity, Aβ toxicity, and glucose deprivation 
(Goodman 1996).  Allopregnanolone increased the number of BrdU labeled cells 
(measure of new cells) and decreased 6E10 staining in the hippocampus of the 3xTg 
mouse model of AD (3xTgAD)(Chen 2011). These data indicate allopregnanolone 
may increase neurogenesis and decrease APP/Aβ levels. Additionally, testosterone 
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reduced AD pathology in the triple transgenic mouse model (Rosario 2012). In 
gonadectomized (GDX) male 3xTgAD mice, testosterone treatment at the time of 
GDX prevented a plaque load increase seen with GDX mice (Rosario 2012). 
Additionally, dihydrotestosterone (DHT), a metabolite of testosterone, increases 
expression of neprilysin (NEP) (Yao 2008). In GDX male rats NEP levels were 
decreased, however when treated with DHT expression of NEP increased to levels 
comparable to that of intact rats. This is important because NEP is a major part of the 
Aβ-catabolizing pathway (Iwata 2000) and in this regard, androgens may be 
beneficial by increasing the amount of NEP available to degrade amyloid plaque.  
 
Alzheimer’s Disease, Estrogens, and Mitochondria 
 Mounting evidence implicates mitochondrial dysfunction as a critical element 
in AD associated neurodegeneration (Mutisya 1994, Bonda 2001, Müller 2010). 
Mitochondria are a major site for reactive oxygen species (ROS) production 
(CITATION). Since, estrogen is an antioxidant, it may play a therapeutic role in 
reducing ROS production and ameliorating oxidative stress in neurological diseases. 
A key discovery in this field was the finding that estradiol receptor (β isoform) 
localizes to the mitochondria, in primary rat neurons, primary cardiomyocytes, and a 
murine hippocampal cell line (Yang 2004). This indicates a potential direct role of 
estrogen in impacting mitochondria. The AD “mitochondrial cascade” hypothesized 
by Swerdlow and Khan (2004) focused on the decline in mitochondrial function with 
age as a catalyst for sporadic AD pathology and symptoms.  Specifically, their 
hypothesis states that baseline mitochondrial function and durability is inherited, 
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which influences how mitochondria change with age, and there is a threshold of 
change at which AD pathology commences (Swerdlow and Kahn 2004).  
 
AD and Mitochondria Differences in mitochondrial function have been shown in the 
human AD population. Their specific connection to the neuropathology of AD is still 
unclear.  However, there is evidence that some mitochondrial enzymes have altered 
activity in AD, such as pyruvate dehydrogenase (PDH) and cytochrome C oxidase 
(COX) (Swerdlow and Kish 2002, Cardoso 2004). In AD patient populations, reduced 
COX activity occurs in platelets (Swerdlow 2007); accompanied by decreased brain 
mitochondria complex I and IV activity and increased reactive oxygen species (ROS) 
level (Navarro and Boveris 2007). There is an interaction between the Aβ protein and 
mitochondria found in both mouse models and humans. In the TgAPP mouse model 
there was an increase in Aβ42 in the synaptic fraction of isolated mitochondria at 12 
months of age (Du 2010). Additionally, the TgAPP model has a reduced respiratory 
control ratio (RCR) at 4 months of age (Du 2010). Combined, these results describe 
early mitochondrial deficits and suggest a relationship to increased Aβ production. In 
a separate study, the triple transgenic (3xTgAD) mice had decreased respiration, 
decreased metabolic enzyme expression and activity, and increased oxidative stress 
compared to age-matched control mice (Yao 2009). These data indicate an early 
deficiency of cellular respiration potentially linked to AD. Interestingly, Aβ has been 
shown to directly associate with and is taken up by, mitochondria (Hansson-Petersen 
2008). Furthermore, the enzyme, Aβ alcohol dehydrogenase (AβAD), has been 
shown to directly associate with Aβ (Pickrell 2009). This interaction of AβAD with 
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Aβ results in inhibition of mitochondrial function, increased ROS, and cytochrome C 
release which initiates cell death (Pickrell 2009). Aβ also interacts with cyclophilin D 
(CypD), a subunit of the permeability transition pore (PTP) . The  proper function of 
CypD is required for normal mitochondrial function. Together these studies suggest a 
direct physical interaction of Aβ with various mitochondrial structures and related 
proteins impacting their function.  
 
Estrogen and Mitochondria In the ovariectomized (OVX) 3xTgAD mouse, females 
treated with estradiol at the time of OVX showed a recovery of mitochondrial 
respiration indicating estradiol may enhance cellular respiration in an OVX system 
(Yao 2011b). In another study, 24hr estradiol incubation in a primary hippocampal 
neuronal culture increased the mitochondrial respiratory capacity of the cells,  
indicating a beneficial role for estrogen at the mitochondrial level (Yao 2011a). These 
data provide further support for a role for estrogen in the mitochondrial respiratory 
deficits and as such, estrogen mimetics may hold promise for future therapeutic 
interventions.  
 
Role of Tau in Mitochondria Tau overexpression has been implicated in 
mitochondrial dysfunction through disruption of trafficking (Kopeikina 2011). This 
interaction has been hypothesized to be due to the known role of Tau in cellular 
trafficking. Vossel and colleagues (2010) found Aβ 1-42 treatment inhibited axonal 
motility of mitochondria in wild type control hippocampal neurons, affecting 
anterograde transport more than retrograde transport. When Tau was reduced via a 
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partial or full knock-out, transport returned to baseline levels (Vossel 2010). These 




 The development of E2Q has allowed for the study of a new class of estradiol 
pro-drug therapeutics (Prokai 2001). As a pro-drug, E2Q, enters the system in the 
quinol form and is metabolized through NADPH reductase (Figure 2), into estrogen. 
This metabolism occurs in the brain at a rate 200x faster than in the body, allowing 
for more of the estrogen parent compound to accumulate in the brain than in the body 
(Gleason 2006). This characteristic is important in avoiding negative peripheral 
effects often seen with hormone replacement therapies (HRT).  
 
 As such, the focus of this research is to test the efficacy of the pro-drug, E2-
Quinol (E2Q), as a potential therapeutic using an AD-relevant mouse model. This 
was accomplished by comparing the effects of E2Q in ovariectomized (OVX) and 
intact female DTG mice.  Additionally, E2Q effects were also examined in males to 
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determine if any gender related differences in responsiveness would emerge. Finally 
we investigated effects of E2Q in males and females of a different AD mouse model, 
the triple transgenic (3xTgAD) model, with a third transgene, TauP301L, to add 
another dimension of AD pathology. Our aim was to detect cognitive benefits, 
molecular changes at the protein level, and mitochondrial level changes in these 









Chapter 2: ESTROGEN PRO-DRUG EFFICACY IN A DOUBLE TRANSGENIC 
MURINE MODEL OF ALZHEIMER’S DISEASE 
Introduction 
 Alzheimer’s disease is characterized by cognitive and neuronal dysfunction 
associated with Amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs). Age 
is the leading risk factor for the development of sporadic AD; however, genetic 
mutations, as in the case of Familial Alzheimer’s Disease (FAD), increase a person’s 
chance of developing AD (Goate 1991; Kamino 1992; Mullan 1992). These human 
genetic variants have been used to create animal models enabling further study of the 
pathology leading to AD. In this study, we used the AD double-transgenic mouse 
(DTG) model of early onset human AD. The DTG model possesses a chimeric 
mouse/human APP Swedish gene (APPSWE, K594M/N595L) as well as the human 
PS1 delta-E-9 (PS1dE9) gene (Jankowsky 2004). This particular model displays 
behavioral deficiencies at 7 months of age (Reiserer et al., 2007), which correlate 
temporally with the appearance of plaques (Jankowsky 2004).  
 Evidence supports the contention that estradiol hormones provide 
neuroprotection within the brain (Brinton 2001, Simpkins 2012); however, peripheral 
effects, including stimulation of estradiol-sensitive cancer and increased risk for 
stroke and heart disease, have diminished their clinical use as a therapeutic. Estradiol 
act on several targets including direct estradiol receptor activation of the mitogen	  
activated	   protein	   kinase/extracellular	   signal-­‐related	   kinase	   (MAPK/ERK) 
pathway as well as the non-receptor mediated antioxidant activity of estradiol thereby 
offering neuroprotection (Brinton 2001, Simpkins 2012). Badeau and colleagues 
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(2005) demonstrated that the antioxidant property of estrogenic compounds is 
associated with the free phenolic hydroxyl group found on the A-ring of the steroid. 
Estradiol treatment up-regulates expression of genes that are protective or associated 
with neuronal survival such as bcl-2, CaMKIIα(+), and Jak1 and 2(+ and -) (Manthey 
and Behl 2006). Additionally estrogen receptor alpha and beta (ERα/β) sub-types 
modulate gene regulation of APP, PS1, and ADAM10, genes affiliated with AD 
(Manthey and Behl 2006). This suggests not only a potential effect at the gene level, 
but also how different receptor subtypes may alter gene expression. Badeau and 
colleagues (2005) demonstrated that the antioxidant property of estrogenic 
compounds is due to the free phenolic hydroxyl group found on the A-ring of the 
steroid. 
 Thus far, the clinical actions of estradiol treatment in aging has focused on 
post-menopausal women. The Women’s Health Initiative (Rossouw 2002)  
investigated the impacts of a combination therapy of conjugated steroid (estradiol and 
progestin) hormone replacement therapy (HRT) on a variety of measures in 
postmenopausal women. The results suggested that HRT exacerbated the occurrence 
of heart disease and breast cancer, thus was halted three years early due to safety 
concerns (Rossouw 2002). Other studies have had more positive outcomes; for 
example, human non-AD subjects receiving estradiol following surgical menopause 
did not suffer memory deficits compared to patients without estradiol (Phillips and 
Sherwin 1992). However, there appears to be a critical time period for efficacy of 
HRT; women who waited to start hormone replacement therapy for 1 year post-
menopause did not regain their memory capacity (Resnick 1997).  Together, these 
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studies suggest a role for estradiol in neuroprotection, emphasize the likelihood of a 
strong temporal component for optimal treatment efficacy.   
 The development of E2-quinol (E2Q) has allowed for the study of a new class 
of estradiol pro-drug therapeutics (Prokai 2001). As a pro-drug, E2Q, enters the 
system in the quinol form and is metabolized through NADPH reducatse, into 
estrogen. This metabolism occurs in the brain at a rate 200x faster in the body, which 
allows for more of the parent compound to accumulate in the brain than in the body 
(Gleason 2006). This characteristic is important in avoiding negative peripheral 
effects often seen with hormone replacement therapies (HRT). The focus of our 
research was an investigation of the efficacy of the pro-drug, E2Q, as a potential 
therapeutic, using a transgenic Alzheimer’s disease mouse model.  The double 
transgenic mouse model (DTG) possesses a chimeric mouse/human APP Swedish 
gene (APPSWE, K594M/N595L) as well as the human PS1 delta-E-9 (PS1dE9) gene 
(Jankowsky 2004).  
 The purpose of this study was to determine the effect of E2Q on behavioral 
and biochemical endpoints in the AD mouse model. Behavioral responses were 
assessed using a radial arm water maze (RAWM), APP and Aβ protein levels, as well 
as overall plaque load in the brain tissue. This study was performed in intact as well 
as OVX animals to determine the effect of endogenous estrogens in the presence of 






Materials and Methods 
Synthesis and Characterization of E2-quinol Compound  Estrogen-derived para-
quinol 17β-dihydroxyestra-1,4-diene-3-one (E2-quinol, E2Q) was synthesized from 
estradiol (E2), as previously reported (Prokai 2001). Briefly, a stirred solution of 
estradiol (E2, 190mg, E8875, Sigma-Aldrich, St. Louis, MO, USA), 3-
chloroperbenzoic acid (m-CPBA, 273031, Sigma-Aldrich, St. Louis, MO, USA), and 
benzoyl peroxide (PhCO)2O2, 33581, Sigma-Aldrich, St. Louis, MO, USA) in 40-60 
ml dry carbon tetrachloride/Me2CO (CCl4/Me2CO, 4:1 v/v) was heated to reflux 
while irradiated with 60 W tungsten lamp (Solaja 1996). Reaction completion was 
verified by thin layer chromatography. The residue was dissolved in CHCl3 and 
washed with saturated NaHCO3 to remove m-chlorobenzoic acid; the organic phase 
was evaporated and the remaining residue was divided into several portions to ensure 
manageability and then purified by column chromatography on silicagel. For 
purification the column was washed extensively with dichloromethane to remove any 
residual E2 followed by elution of E2Q with ethylacetate/dichloromethane mixture 
(CH3COOCH2CH3/CH2Cl2, 9:1, v/v). The purity of the compound (white solid) was 
verified by high performance liquid chromatography (HPLC), liquid 
chromatography/mass spectrometry (LC/MS) and gas chromatography/mass 
spectrometry (GC/MS). Purity of the final product was >99% with no trace amounts 
of the starting material.  
 
Animal Husbandry Transgenic APPswe/PS1dE9 (B6.Cg-Tg (APPswe, 
PSEN1dE9)85Dbo/J,   Jackson Labs, Bar Harbor, ME, USA) mice were obtained at 
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3-4 months of age from the colony of Dr. Rosemary Schuh maintained at the 
Veterans Affairs Maryland Health Care System (Baltimore, MD). Animals were 
received and transferred following Institutional Animal Care and Use Committee 
(IACUC) approved protocols. The APPswe/PS1dE9 hemizygote genotype was 
maintained by crossing a female wild-type (C57BL/6, #000664, Jackson Labs, Bar 
Harbor, ME, USA) with a male APPswe/PS1dE9.  Animals were purchased, bred on 
site and weaned at 21-25 days of age, then tail snipped and genotyped at 30-35 days 
of age. Animals were group housed by gender in an environmentally controlled 
animal facility on a 12-hour light/dark schedule. Food and water were provided ad 
libitum at the University of Maryland College Park. All animal care and experimental 
procedures were conducted under the University of Maryland, College Park IACUC 
approved protocols. To minimize any confound, due to estrogenic compounds in the 
diet, experimental animals were maintained on a phytoestrogen free diet (#AIN-93G, 
Bio-Serv, Frenchtown, NJ, USA), which was begun one week prior to initiating the 
study. Animals were individually housed following surgical procedures (see below 
for details).  
 
Experimental Design 
Treatments Female transgenic (DTG) and wild type mice (5.5-6 months) were treated 
with vehicle (propylene glycol, #P4347, Sigma-Aldrich, St. Louis, MO, USA), E2 
(2ug/day, #, Sigma-Aldrich, St. Louis, MO, USA), or E2Q (2ug/day) (N = 7-9) (See 
Table 1). Animals were divided into cohorts containing individuals from each 
treatment group to conduct the study with smaller manageable numbers of animals 
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over the time required to complete the entire study. Further, this allowed for direct 
comparison of treatment effects on neural and behavioral responses. The long ½ life 
of E2Q allowed us to administer the treatment using Alzet osmotic minipumps 
(#2004, 0.25ul/min, Durect Corp., Cupertino, CA, USA). The minipumps delivered 
the appropriate doses over the 8-week period of treatment; pumps were replaced once 
at the 4-week time point. Release of the compound was confirmed by measuring 
circulating levels using an estradiol immunoassay.  Compounds were dissolved in 
USP-grade propylene glycol (#P355, Fisher Scientific, Pittsburgh, PA, USA) in 
which both estrogen and E2Q are freely soluble and compatible with Alzet pumps. 
Animals were lightly anesthetized using isoflurane at an appropriate dose for mice 
according to the IACUC recommendation (IACUC 2012). After anesthetization, a 
small patch of hair was removed from the upper back of the mouse and the area 
disinfected. A small incision was made on the operative area and the Alzet osmotic 
pump implanted subcutaneously between the scapulae. The incision was closed, 
sutured and allowed to heal. Following surgery, animals recovered on a surgical grade 
(#DCT-15, Kent Scientific Instruments, Torrington, CT, USA) heating pad under 
continuous observation before being placed in a cage containing clean, dry bedding. 
No special post-operative care was generally required. Animals were monitored daily 
for possible infection and to ensure each individual maintained a healthy body 
weight, and there were no adverse effects. 




Intact OVX Intact OVX 
Vehicle 7 7 7 7 
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E2  9 7 8 8 
E2-Quinol  9 7 7 7 
 
Ovariectomy One-half of the females in each treatment group were surgically 
ovariectomized (OVX) immediately prior to initiating treatment. The surgical 
procedure was conducted as follows: an incision (1.5 cm) was used to open the 
intraperitoneal cavity exposing the muscle layers and the ovaries. The ovarian artery 
was clamped bilaterally and cut near the ovary. Clamps were removed after bleeding 
had ceased, and when necessary, absorbable suture (#J392H-RL 4-0 FS-2, Ethicon, 
Somerville, NJ, USA) used. The muscle layer was closed using a continuous stitch 
with absorbable suture, and the skin layer was closed using an interrupted stitch with 
non-absorbable suture (#8683G-RL 4-0 FS-2, Ethicon, Somerville, NJ, USA). 
Following surgery, animals recovered on a surgical grade-heating pad (#DCT-15, 
Kent Scientific Instruments, Torrington, CT, USA) and remained under continuous 
observation before being placed in a cage, on clean, dry bedding. No special post-
operative care was generally required. Animals were monitored daily for possible 
infection and normal behavior.  
 
Estradiol EIA An estradiol (E2) EIA 17β-Estradiol kit (#582251, Cayman chemicals, 
Ann Arbor, MI, USA) was validated for parallelism of measurements, sensitivity, 
accuracy, and precision. Standards and samples were prepared according to the 
manufacturer’s instructions and samples were diluted using the assay buffer when 
necessary. Standards, blanks, and samples were incubated with tracer and antiserum 
for one hour at room temperature and then washed; Ellman’s reagent was added to the 
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wells and plates were incubated for one hour at room temperature in the dark. 
Absorbance was read at 405nm (#680 Microplate Reader, Bio-Rad, Hercules, CA, 
USA) 60 minutes post development. Inter- and intra-assay variation were less than 
5% and 10%, respectively (Data not shown).  Charcoal stripped serum from male 
non-transgenic mice spiked with E2Q (10ug) showed less than 10% cross reactivity. 
The EIA cross reacts with estrone (12%) and estriol (0.30%). Serum estrogen levels 
were measured at 0, 4, and 8 weeks of treatment to measure estrogen levels to check 
for completeness of ovariectomy and for release of compounds by the implants.  
 
Uterine Wet Weight Uterine wet weight was utilized to determine estrogen 
stimulation of uterine tissue. Uterine wet weight was measured at euthanasia by 
removal and gram weight measurement of the uterus. Body weight across treatment 
groups did not differ therefore uterine weight was not adjusted for body weight 
(Jefferson 2009).  
 
Radial Arm Water Maze (RAWM) Behavioral Testing A radial-arm water maze test 
(Alamed 2006) was used to measure cognitive deficits in the mice post-treatment 
period. This test is designed as a water maze with 6 arms radiating out from the 
central pool area. The platform is placed at the end of the goal arm (specific for each 
mouse) for the animal to locate. A large plastic tub was spray-painted black and 
visual cues (3-D objects) were placed at the end of each arm on the wall of the pool. 
Mice received one day of training (Day 1) involving 12 trials alternating between a 
hidden and visible platform followed by 3 trials of all hidden platform training. Days 
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2 and 3 consisted of 15 hidden platform test trials. Each mouse was assigned one goal 
arm, which remained constant throughout the three testing days. The start arm 
changed for each trial and mice had 60 seconds to reach the platform. If they did not 
locate the platform within 60 seconds the mouse was gently directed to the platform 
and allowed to rest for 10 seconds before being removed from the pool. An error was 
recorded as an entry (all four paws) into an incorrect arm or entry into the goal arm 
without successful location of the platform. Latency was recorded as the time in 
seconds it took the animal to locate the platform correctly. All animals were scored 
by the same observer who stood in the same place during testing to eliminate themself 
as a visual cue.   
 
Tissue Collection Following the RAWM protocol animals were euthanized by 
cervical dislocation and the brain was immediately removed and each half flash 
frozen for storage at -80°C. For analysis, the brain sample was homogenized using 
1ml of homogenization buffer (225mM ultra pure mannitol, 75mM ultra pure sucrose, 
5mM Hepes, 1mM EGTA, pH to 7.4 at 4˚C, Sigma-Aldrich, St. Louis, MO, USA). 
Homogenate protein levels were measured using the standard Lowry (1951) protein 
assay (Protein Assay Reagent A (#500-0113) and Protein Assay Reagent B (#500-
0114), Bio-Rad, Hercules, CA, USA). The other half of each brain was post-fixed in 
4% paraformaldehyde and transferred to 30% sucrose after 24 hours. Tissue was 
allowed to sink in the sucrose solution ensuring full saturation of the tissue before 





Processing and Immunochemistry for APP Serial sections of 50um thickness were 
collected using a freezing microtome (#860, American Optical AO, Buffalo, NY, 
USA) and sections stored in cryobuffer (30% Sucrose (#S5-3, Fisher Scientific, Fair 
Lawn, NJ, USA) 1% polyvinylpyrrolidone (#BP431, Fisher Scientific) 30% ethylene 
glycol (#102466, Sigma-Aldrich) until staining was performed. Tissue was washed in 
1x TBS to remove cryobuffer residue and treated with 1% hydrogen peroxide (H2O2) 
(30 min, #325-100, Fisher Scientific) to block endogenous peroxidase activity. Tissue 
was then washed in 1x TBS and treated with 0.3% Triton X-100 in 1X phosphate 
buffered saline (PBS) (10min, #BP151, Fisher Scientific) followed by 5% Normal 
Goat Serum (NGS) (30 min, #S-1000, Vector Labs, Burlingame, CA, USA). Tissue 
was incubated with primary antibody overnight at 4°C while on a shaker. Amyloid 
isoforms and soluble APP were identified using antibodies against APP (6E10) 
(1:300, #39340, Covance, Princeton, NJ, USA). After incubation, tissue was washed 
and treated with the Vectastain ABC kit (90 min, #PK-6100, Vector Labs, 
Burlingame, CA, USA), washed again, then exposed to the secondary antibody 
(90min, biotinylated anti-Mouse IgG, #BA-9200, Vector Labs, Burlingame, CA, 
USA). For color development the tissue was treated with 3,3’-diaminobenzidine 
tetrahydrochloride (DAB, #D5905, Sigma-Aldrich, St. Louis, MO, USA) for 5 
minutes. Tissue was immediately washed in 1x TBS, mounted on subbed slides 
(#OBSLD01CS, Fisher Scientific), and allowed to dry overnight on slides before 




Semi-quantitative Measurement of Immunostaining Images were captured using an 
AxioCam MR camera and AxioVision image capture software (Zeiss, Houston, TX, 
USA). Quantification of plaque number was performed using ImageJ software (NIH, 
Bethesda, MD, USA). Five tissue sections spanning the hippocampus were analyzed 
in each individual. Measurements were taken at 2,5X magnification for the entire 
hippocampal region (CA1, CA2, CA3, and dentate gyrus) as well as the surrounding 
cortex, including arcuate nucleus, motor cortex, and somatosensory cortex. Color de-
convolution was used to separate the DAB from the cresyl violet stain. Images were 
transformed to 8-bit gray scale images and stain threshold was adjusted to select for 
visually observed plaques. Computer generated number of plaques within one frame 
was recorded. The measurements from the 5 tissue slices analyzed were averaged for 
each animal.  
 
Biochemical Measurements 
Western Blot for APP Protein concentrations were measured on the brain 
homogenates (25ug total protein) by Western blot analysis. Western blots were 
performed using 10% Bis-Tris gel (#456-1046,Bio-Rad, Hercules, CA, USA) and 
samples were normalized to the housekeeping protein β-actin (#4967, Cell Signaling, 
Danvers, MA, USA) . Briefly, samples were boiled at 95 °C for 15 minutes in the 
presence of loading buffer ((25ul) β-mercaptoethanol (#M6250 Sigma) (475ul) 
Laemmli buffer (#161-0737, Bio-Rad)), vortexed and spun down before being loaded 
onto a 10% Bis-Tris gel. Samples were run at 200v for 30 minutes before being 
transferred to an Immobilon FL PVDF membrane (#IPFL00010, Millipore, Billerica, 
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MA, USA) using the transblot turbo transfer system (#170-4155, Bio-Rad) at 2.5A, 
10v for 10 minutes. Membranes were blocked (60 min; #927-40000, LiCor, Lincoln, 
NE, USA) then incubated with primary antibodies against amyloid precursor protein 
(6E10, #39340, Covance, Princeton, NJ, USA) and the housekeeping protein β-actin 
overnight at 4°C. Membranes were then incubated with secondary anti-mouse (6E10) 
and anti-rabbit (β-actin) iRdye antibodies (#827-08366 and #926-32211, LiCor,) and 
imaged on the LiCor Odyssey system and densitometry was performed using 
Odyssey software (Licor,). Measurements were converted to a ratio of APP:Actin.  
 
Amyloid Beta ELISA Total Aβ1-40 and Aβ1-42 was quantified using a commercially 
available ELISA kit ((40) #KHB3481 and (42) #KHB3441, Invitrogen, Grand Island, 
NY, USA). Briefly, standards provided by the company, and samples were measured 
using a monoclonal primary (rabbit) antibody specific for the NH2-terminus region of 
human Aβ 1-40 or 1-42. The bound primary antibody was detected using a horseradish 
peroxidase-labeled anti-rabbit antibody. Finally a stabilized chromagen solution was 
added which causes a color change directly proportional to the amount of human Aβ 
present in the sample. Absorbance was measured at 450nm using a Victor microplate 
reader (Wallac #1420, Perkin Elmer, Waltham, MA, USA). Final concentration values 
of Aβ were calculated as pg/mg protein.  
 
Statistical Analyses  
All statistical analyses were performed using the JMP software program (Version 
10.0, SAS Institute, Inc., Cary, NC, USA).  
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Multivariate Analysis Behavioral results were analyzed using a multivariate, 
MANOVA, analysis.  
One-Way ANOVA One-way ANOVA was performed for all analyses. Post-hoc 
analysis was performed using the Tukey Kramer HSD test to compare each treatment 
group to each other (Table 2). 
Table 2.2. Statistical Comparisons were made between groups in each cell by Tukey 
HSD.  
Tukey Test Comparisons 
Biologically Relevant Comparisons Non-Biologically Relevant Comparisons 
NTG VEH – DTG VEH  NTG VEH  – DTG E2  
NTG VEH – NTG E2  NTG VEH – DTG E2Q  
NTG VEH – NTG E2Q  NTG E2  – DTG E2Q  
NTG E2 – NTG E2Q  NTG E2 – DTG VEH  
NTG E2 – DTG E2   
DTG VEH – DTG E2   
DTG VEH – DTG E2Q   
DTG E2 – DTG E2Q   




Estrogen levels measured by EIA Circulating estradiol levels were measured to 
confirm ovariectomy (OVX) and release of compounds from the osmotic pump 
(Figure 1). We did not attempt to quantify the concentration of E2Q released due to 
the low cross reactivity (<10%) of the estradiol antibody with the quinol compound. 
Results showed that OVX females had extremely low or non-detectable estradiol 
levels, verifying the complete removal of the ovaries. Serum was collected at 0, 4, 
and 8 weeks of treatment. The OVX females receiving the vehicle did not have 
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detectable levels of estrogen at 4 weeks of treatment as compared to intact vehicle 
treated females (NTG p = 0.0021, DTG p < 0.0001). Low endogenous estrogen due to 
OVX was also seen at 8 weeks of treatment (NTG p = 0.0084, DTG p < 0.0001) 
(Figure 1). OVX females receiving E2 or E2Q had detectable levels of estrogen, 
similar to those of intact vehicle treated females (Figure 1). Additionally intact 
females treated with E2 had significantly higher levels of estrogen at 8 weeks of 
treatment (NTG, p = 0.0009 DTG, p = 0.0002) (Figure 1), as did intact females 
treated with E2Q (NTG, p = 0.0084 DTG, p = 0.0180).  
 
Uterine wet weight measurement Uterine wet weight was measured as gram weight of 
the uterine tissue. There was a significant difference (p<0.0001) between the vehicle 
and E2Q treated groups and the E2 groups (Figure 2). E2Q treated mice had wet 
weight measurements that were not significantly different from vehicle treated groups 
(Figure 2).  
 
RAWM behavioral testing Initial differences in errors and latency between the NTG 
and DTG vehicle treated groups were observed.  
 Intact females On day 1 the intact vehicle treated DTG females 
performed significantly more errors than the NTG vehicle treated females (p = 
0.0002), DTG E2 treated females (p = 0.0119), and DTG E2Q treated females (p = 
0.0321) (Figure 3A). There were no significant differences observed in the intact 
females across groups on day 2 of testing. On day 3 of testing, the intact vehicle 
treated DTG females performed significantly more errors than the DTG E2 treated 
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females (p = 0.0321) as well as the DTG E2Q treated females (p = 0.0119) (Figure 
3A). 
  OVX females On day 1 the OVX vehicle treated DTG females 
performed significantly more errors than the NTG vehicle treated OVX females (p = 
0.0019) (Figure 3B). Additionally DTG E2 treated OVX females performed 
significantly more errors than the NTG E2 treated OVX females (p = 0.0012). 
Interestingly, there was no significant difference in errors performed between the 
NTG E2Q and DTG E2Q treated OVX females. On day 2 of testing OVX vehicle 
treated DTG females still made more errors as compared to the NTG vehicle treated 
OVX females (p = 0.0026) (Figure 3B). Also the DTG E2 treated OVX females 
performed more errors than the NTG E2 treated OVX females (p = 0.0090). There 
was no significant difference observed between the NTG E2Q and DTG E2Q treated 
OVX females on day 2. On day 3 the DTG E2 (p = 0.0038) and DTG E2Q (p = 
0.0147) treated OVX females performed less errors than the DTG vehicle treated 
OVX females (Figure 3B). 
 
APP levels decrease in intact but not OVX females Baseline differences were 
apparent in the significantly higher level of full length APP in the DTG vehicle 
treated females as compared to the NTG vehicle treated females (p = 0.0248) (Figure 
4A). APP levels significantly decreased in the DTG E2 (p = 0.0004) and E2Q (p < 
0.0001) treated females as compared to the vehicle treated DTG intact females 
(Figure 4A). Additionally the NTG E2 treated intact females had a significantly lower 
amount of APP compared to the vehicle treated NTG intact females (p<0.0025) 
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(Figure 4A). There were no significant differences in APP levels observed across 
treatment groups in the OVX females (Figure 4B).  
 
Aβ40 and 42 are reduced in E2 and E2Q treated females Aβ levels in E2 and E2Q 
treatment groups decreased in OVX females and intact females.  
 Aβ40 In the DTG OVX females, Aβ40 was significantly decreased in 
the E2 treated females (p < 0.0001) and the E2Q treated females (p < 0.0001) as 
compared to the DTG vehicle treated OVX females (Figure 5A). In the intact females 
the amount of Aβ40 in the DTG E2 treated females (p = 0.0002) and DTG E2Q 
treated females (p = 0.0014) were significantly lower as compared to the DTG vehicle 
treated females (Figure 5B).  
 Aβ42 In OVX females, Aβ42 in the DTG E2 treated females (p < 
0.0001) and E2Q treated females (p < 0.0001) were significantly decreased as 
compared to DTG vehicle treated females (Figure 5A). Additionally, the amount of 
Aβ42 in OVX E2 treated DTG females was significantly higher than the E2Q treated 
DTG females (p = 0.0398) (Figure 5A). In the intact females, Aβ42 in the DTG 
vehicle treated females were significantly higher than the amount of Aβ42 in the E2 
(p = 0.0133) and E2Q (p = 0.0139) treated DTG OVX females (Figure 5B). 
 
Hippocampal and cortex amyloid plaque load Immunohistochemistry for 
measurement of the number of amyloid plaques occurring within the hippocampus 
and cortex of DTG mice showed no plaques in the NTG treatment groups (Figure 6). 
Plaque was present in the DTG groups however no differences were observed across 
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the DTG treatment groups, both in the intact and OVX females (Figure 6). There was 





Release and Peripheral Effects of E2Q A novel compound was tested for efficacy 
in providing neuroprotective effects of estrogen while avoiding adverse peripheral 
effects associated with estrogen. Although the EIA had limited cross-reactivity 
(<10%) with the quinol compound, there was sufficient E2Q measured in the plasma 
samples from treated females to demonstrate effective release of the compound from 
the minipumps.  Uterine tissue was not stimulated by the E2Q compound. This 
confirms previous research (Prokai, Personal Communication) showing little or no 
stimulation of peripheral steroid sensitive tissues by E2Q. Importantly, no adverse 
effects were observed throughout the duration of the study. 
Behavioral Effects of Estradiol and E2Q The DTG mouse model has shown 
cognitive deficits at 6 months of age in previous studies (Jankowsky 2005; 
Savonenko 2005). Our behavioral results mirrored this finding; an initial difference 
existed on day 1 of testing between the NTG vehicle treated females and the DTG 
vehicle treated females in both the intact and OVX groups. These initial differences 
have also been observed using a Barnes maze testing paradigm in this mouse model 
(Reiserer 2007). These initial deficits are rescued in the intact group by day 3 of 
testing in both the E2 and E2Q treated females. These positive results indicate that 
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E2Q is beneficial in our mouse model of AD and thus may be a promising therapeutic 
to pursue in humans. Since these benefits were seen in the OVX animals, E2Q may 
be beneficial for menopausal women. Further investigation is needed to discern how 
E2Q acts on behavioral circuits to the alter response. One issue with the behavioral 
tests we conducted is that our test was a short-term test (3 days), a longer testing 
period may reveal other differences among the treatment groups. There are many 
behavioral tests focusing on hippocampal dependent functions, such as the classic 
Morris water maze (MWM), (Morris 1982) which is specific for hippocampal 
function and does not use food or water motivation (Bryan 2009). Alternatively the 
radial arm maze  (RAM) tests short and long-term memory, but does use food or 
water as a reward. Additionally, fear conditioning tests contextual memory, a measure 
of amygdalar-hippocampal communication, which assesses hippocampal function that 
is different from the type of memory used in a spatial task (Bryan 2009). A battery of 
cognitive tests would be beneficial in obtaining information about short-term and 
long-term memory as well as amygdala related memory within this treatment 
paradigm.  
Effect of E2Q on APP Our data showed that both the E2 and E2Q intact treated 
animals showed an overall decrease in APP levels measured in brain homogenate. 
This complements previous research, which showed that estrogen activation of the 
estrogen receptor (both α and β subtypes) down-regulates the APP gene (Manthey 
and Behl 2006). Based on this previous research, we can speculate that our current 
findings may be a result of a gene level effect, however further studies must be 
performed to determine the accuracy of that hypothesis. Potentially, the decrease in 
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APP could be beneficial to an AD patient as a pathway to decrease overall Aβ 
production and subsequent plaque formation. It is important to remember, APP does 
have endogenous functions that are necessary for cellular process, and this fact must 
be considered when using a therapeutic that effects overall APP levels.  
Impact on Aβ 40 and 42 As with APP, there was a decrease of Aβ 40 and 42 with 
E2 or E2Q treatment. With less APP we would expect less Aβ, but we cannot 
confirm if this decrease in Aβ is due to the decrease in APP or a result of Aβ 
degradation. Previously estriol (E3), which is less biologically active than estradiol, 
was shown to inhibit Aβ oligomer formation in vitro and may be a mechanism 
producing Aβ product (Morinaga 2011). Since plaque formation is apparent by 6 
months in this DTG model, a decrease at this time point indicates the quinol may be 
useful as a therapeutic in the early stages of visible pathology.  
Plaque Load in E2Q Treated Mice Overall plaque load did not decrease in number 
in either the E2 or E2Q treatment groups.  These results indicate that while there was 
a decrease in APP and Aβ protein levels, neither E2 nor E2Q were effective in 
degrading plaques that had already formed by the time we initiated treatment. This 
suggests that these interventions may not be able to reverse already formed plaques 
but could affect further production or accumulation of APP protein, Aβ fragments, 
and Aβ plaques. Additionally in the OVX and intact animals we did see a slight 
difference in plaque load, which has been shown before (Yao 2012), however our 
data was not significant. 
 In summary, the E2 and E2Q treatments were beneficial in a number 
of endpoints. We observed decreased number of errors in the DTG E2Q treated 
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groups by the third day of testing as well as decreased APP and Aβ protein, all 
without any uterine tissue stimulation. These beneficial effects on cognitive and 
molecular measures without the characteristic of uterine stimulation makes the E2Q a 
potentially useful therapeutic tool without the deleterious effects of estradiol. As 




































Chapter 3: MITOCHONDRIAL RESPONSE TO AN ESTROGEN PRO-
DRUG IN A MURINE MOUSE MODEL OF ALZHEIMER’S DISEASE 
 
Introduction  
 Recent research has implicated mitochondrial dysfunction as an early 
consequence as well as a primary cause in neurodegenerative disease. The 
“mitochondrial cascade” hypothesis originally introduced by Swerdlow and Kahn 
(2004) points to mitochondrial decline with age as a catalyst for sporadic Alzheimer’s 
disease (AD) pathology and symptoms. This hypothesis states that 1) inheritance 
determines mitochondrial integrity, 2) baseline integrity changes with age, and 3) 
when these changes reach a threshold AD pathology commences (Swerdlow and Kahn 
2004). While research has helped to elucidate the mechanisms at work in the 
mitochondrial pathway, questions remain regarding the mechanistic connections 
between mitochondrial dysfunction and AD pathology. 
 Mitochondrial deficiencies and increased reactive oxygen species (ROS) have 
been documented in human AD (Swerdlow and Kish 2002, Cardoso 2004, Navarro 
and Boveris 2007). AD patients produce excessive ROS and a deficiency of 
mitochondrial respiratory complex IV (cytochrome c oxidase, COX); thereby, 
suggesting a deficiency in mitochondrial function (Cardoso 2004).  Additionally, lipid 
peroxidation can result from excess ROS within a cell. In patients diagnosed with mild 
cognitive impairment (MCI), increased lipid peroxidation was identified as an early 
event in dementia related degenerative diseases (Markesbery 2005). Additionally, the 
same study saw increased lipid peroxidation levels in patients with late-stage AD 
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(Markesbery 2005). Together, these studies demonstrate a prevalence of disruptions in 
AD patients that may play a role in mitochondrial dysfunction. Furthermore, healthy 
cell functioning requires appropriate activity of ROS degrading enzymes including 
superoxide dismutase (SOD) and catalase (CAT). In AD patients, an increase in the 
cytosolic copper-zinc SOD (CuZn-SOD) protein levels were observed while the 
activity of the CuZn-SOD remained unchanged (Puertas 2012). In this same study 
CAT activity decreased while the protein level was unchanged (Puertas 2012). These 
findings indicate the relative importance of functional activity versus protein levels, 
which must be defined in the AD studies. These differences may prove to be very 
important in determining the underlying mechanisms of cellular respiration 
disruptions.  
  Researchers are exploring the link between mitochondrial function and 
neurodegenerative diseases such as the interaction of amyloid precursor protein 
(APP), amyloid-beta (Aβ), and mitochondria. It is known that mitochondria take up 
Aβ via the translocase of the outer mitochondrial membrane (TOM) (Hansson 
Petersen 2008). While transport of APP occurs through the TOM protein, APP has 
been found to accumulate within the TOM channel (Lin and Beal 2006), potentially 
disrupting mitochondrial function. Additionally the Avadhani lab (2006) showed that 
amyloid precursor protein could be succesfully targeted to mitochondria isolated from 
an AD transgenic mouse model as well as human AD brain (Anandatheerthavarada 
2003, Devi 2006). Taken together these data suggest a role for APP and Aβ in direct 




 Estrogens have been shown to effect mitochondria (CITATION), more 
importantly, it is known that the estrogen receptor beta sub-type (ERβ) localizes to 
the mitochondria (Simpkins 2004). While estrogens are known to be neuroprotective, 
their negative peripheral effects (Van Gorp and Neven 2002, Rossouw 2002) have 
limited their use as a therapeutic in neurodegenerative diseases. Estrogens provide 
various routes of neuroprotection such as direct estrogen receptor activation of the 
MAPK/ERK pathway and non-receptor mediated antioxidant activity (Brinton 2001 
and Simpkins 2012). Estradiol has been shown to improve depressed mitochondrial 
respiration in a 3xTgAD OVX system (Yao 2011b). A separate study showed 
administration of estradiol increased mitochondrial respiratory capacity, again 
indicating a beneficial role for estrogen in relation to mitochondria (Yao 2011a). 
Based on animal studies, therapeutics using estrogen mimetics may provide 
interventions, however, within the AD population therapeutic studies aimed at 
mitochondrial endpoints have yet to be rigorously assessed.  
 In this study the effect of E2-Quinol (E2Q), a pro-drug, was assessed for 
electron transport chain protein levels, lipid peroxidation, and antioxidant levels in 
ovariectomized (OVX) and intact females of the DTG mouse model.  The 
development of E2Q has allowed for the study of a new class of estradiol pro-drug 
therapeutics (Laszlo 2001). As a pro-drug, E2Q, enters the system in the quinol form 
and is metabolized through NADPH reductase, into estrogen. This metabolism occurs 
in the brain at a rate 200x faster than in the body (Gleason 2006). This high rate of 
metabolism allows for more of the estrogen parent compound to accumulate in the 
brain than in the body. This characteristic is important in avoiding negative peripheral 
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effects often seen with hormone replacement therapies (HRT) (Van Gorp and Neven 
2002 and Rossouw 2002).  The purpose of this study was to determine the effect of 
E2Q on various mitochondrial endpoints in the DTG AD mouse model. We measured 
protein levels of the five electron transport chain protein complexes (I-V), total 
superoxide dismutase activity, catalase activity, and lipid peroxidation. This study 
was performed in intact as well as OVX animals to determine the effect of 
endogenous estrogens in the presence of our treatment paradigm. We report that E2Q 
treatment was successful in both intact and OVX animals, with no uterine tissue 
stimulation in E2Q treated animals. Additionally there was increase in complex III 
and IV protein levels in the OVX DTG E2Q treated animals. These results indicate 
E2Q may be beneficial for electron transport chain protein levels in an OVX system.  
  
Materials and Methods 
Synthesis and Characterization of E2-quinol Compound Estrogen-derived para-quinol 
17β-dihydroxyestra-1,4-diene-3-one (E2-quinol, E2Q) was synthesized from estradiol 
(E2), as previously reported (Prokai 2001). Briefly, a stirred solution of estradiol (E2, 
190mg, E8875, Sigma-Aldrich, St. Louis, MO, USA), 3-chloroperbenzoic acid (m-
CPBA, 273031, Sigma-Aldrich, St. Louis, MO, USA), and Benzoyl peroxide 
(PhCO)2O2, 33581, Sigma-Aldrich, St. Louis, MO, USA) in 40-60 ml dry carbon 
tetrachloride/Me2CO (CCl4/Me2CO, 4:1 v/v) was heated to reflux while irradiated 
with 60 W tungsten lamp (Solaja 1996). Reaction completion was verified by thin 
layer chromatography. The residue was dissolved in CHCl3 and washed with 
saturated NaHCO3 to remove m-chlorobenzoic acid; the organic phase was 
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evaporated and the remaining residue was divided into several portions to ensure 
manageability and then purified by column chromatography on silicagel. For 
purification the column was washed extensively with dichloromethane to remove any 
residual E2 followed by elution of E2Q with ethylacetate/dichloromethane mixture 
(CH3COOCH2CH3/CH2Cl2, 9:1, v/v). The purity of the compound (white solid) was 
verified by high performance liquid chromatography (HPLC), liquid 
chromatography/mass spectrometry (LC/MS) and gas chromatography/mass 
spectrometry (GC/MS). Purity of the final product was >99% with no trace amounts 
of the starting material.  
 
Animal Husbandry Transgenic APPswe/PS1dE9 (B6.Cg-Tg (APPswe, 
PSEN1dE9)85Dbo/J,   Jackson Labs, Bar Harbor, ME, USA)  mice were obtained at 
3-4 months of age from the colony of Dr. Rosemary Schuh maintained at the 
Veterans Affairs Maryland Health Care System (Baltimore, MD). Animals were 
received and transferred following IACUC approved protocols. The APPswe/PS1dE9 
hemizygote genotype was maintained by crossing a female wild-type (C57BL/6, 
000664, Jackson Labs, Bar Harbor, ME, USA) with a male APPswe/PS1dE9.  
Animals were purchased, bred on site and weaned at 21-25 days of age then tail 
snipped and genotyped at 30-35 days of age. Animals were group housed by gender 
in an environmentally controlled animal facility on a 12-hour light/dark schedule. 
Food and water were provided ad libitum at the University of Maryland College Park. 
All animal care and experimental procedures were conducted under the University of 
Maryland, College Park Institutional Animal Use and Care Committee (IACUC) 
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approved protocols. To minimize any confounding factor of estrogenic compounds in 
the diet, one week prior to experimental treatment animals were placed on a 
phytoestrogen free diet (AIN-93G, Bio-Serv, Frenchtown, NJ, USA) to eliminate 




Treatments Female Transgenic and wild type mice (5.5-6 months) were treated with 
vehicle (propylene glycol, P4347, Sigma-Aldrich, St. Louis, MO, USA), E2 
(2ug/day), or E2Q (2ug/day) (N = 7-9) (See Table 1). Animals were divided into 
cohorts where all treatment groups were represented for behavioral testing and to 
eliminate potential seasonal effects Due to the long ½ life of E2Q, the Alzet osmotic 
minipumps (#2004, 0.25ul/min, Durect Corp., Cupertino, CA, USA) were used to 
deliver the appropriate dose over the 8-week treatment period. Pumps were replaced 
once, at the 4-week time point. Compound release was confirmed by measuring 
circulating levels of estradiol using an enzyme immunoassay.  Compounds were 
dissolved in USP-grade propylene glycol (P355, Fisher Scientific, Pittsburgh, PA, 
USA) in which both estrogen and E2Q are freely soluble and compatible with Alzet 
pumps. Animals were lightly anesthetized using isoflurane at an appropriate dose for 
mice according to the IACUC recommendation (IACUC 2012). After anesthetization, 
a small patch of hair was removed from the upper back of the mouse and the area 
disinfected. A small incision was made on the operative area and the Alzet osmotic 
pump implanted subcutaneously between the scapulae. The incision was closed, 
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sutured and allowed to heal. Following surgery, animals recovered on a surgical grade 
(DCT-15, Kent Scientific Instruments, Torrington, CT, USA) heating pad under 
continuous observation before being placed in a cage containing clean, dry bedding, 
atop a heating pad. No special post-operative care was generally required. Animals 
were monitored daily for possible infection and to ensure wounds remained clean, the 
animals maintained a healthy body weight, and there were no adverse effects. 




Intact OVX Intact OVX 
Vehicle 7 7 7 7 
E2  9 7 8 8 
E2-Quinol  9 7 7 7 
 
Ovariectomy One-half of the females in each treatment group were surgically 
ovariectomized (OVX) immediately prior to treatment. The surgical procedure was 
conducted as described in chapter 2. Briefly, ovarian tissue was removed and the 
ovarian arteries clamped until bleeding ceased.  When necessary, absorbable suture 
(J392H-RL 4-0 FS-2, Ethicon, Somerville, NJ, USA) was used. The skin layer was 
closed using non-absorbable suture (8683G-RL 4-0 FS-2, Ethicon). Following 
surgery, animals were monitored daily for possible infection and normal behavior.  
 
Estradiol EIA An estradiol (E2) EIA 17β-Estradiol kit (582251, Cayman chemicals, 
Ann Arbor, MI, USA) was validated and used to measure estradiol in serum samples 




Uterine Wet Weight Uterine wet weight was previously reported (Chapter 2).  
 
Tissue Collection Following Animals were euthanized by cervical dislocation. Brain 
was immediately removed and half of each brain was flash frozen for storage at -80C. 
For analysis, the brain sample was homogenized using 1ml of homogenization buffer 
(225mM ultra pure mannitol, 75mM ultra pure sucrose, 5mM Hepes, 1mM EGTA, 
pH to 7.4 at 4˚C, Sigma-Aldrich, St. Louis, MO, USA). Homogenate protein levels 
were measured using the standard Lowry protein assay (Protein Assay Reagent A 
(500-0113) and Protein Assay Reagent B (500-0114), Bio-Rad, Hercules, CA, USA) 
(Lowry 1951). The other half of each brain was post-fixed in 4% paraformaldehyde 
and transferred to 30% sucrose after 24 hours. Tissue was allowed to sink in the 




Western Blot for Mitochondrial Proteins Complex I-V Protein levels were measured 
on brain homogenates by Western blot analysis. Western blots were performed using 
a 10% Bis-Tris gel (#456-1046,Bio-Rad) and samples were normalized to 25ug 
protein. Briefly, samples were boiled at 95 °C for 15 minutes in the presence of 
loading buffer ((25ul) Beta-Mercaptoethanol #M6250 Sigma, St. Louis, MO, USA 
and (475ul) Laemmli Buffer 161-0737, Bio-Rad), vortexed and spun down before 
being loaded onto the gel. Samples were processed through the gel at 200v for 30 
minutes. Gels were then transferred to an Immobilon FL PVDF membrane 
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(IPFL00010, Millipore, Billerica, MA, USA) using the transblot transfer system (170-
4155, Bio-Rad) at 2.5A, 10v for 10 minutes. Membranes were blocked ((60 min) 927-
40000, LiCor, Lincoln, NE, USA) before being incubated with primary antibodies 
against one subunit of each of the five proteins of the electron transport chain, 
complexes I-V (OxPhos Cocktail, MS604, Mitosciences, Eugene, OR, USA) and the 
housekeeping protein beta-actin (4967, Cell Signaling, Danvers, MA, USA). 
Membranes were then exposed to secondary anti-mouse (OxPhos) and anti-rabbit 
(beta-actin) IRdye antibodies (827-08366 and 926-32211, LiCor). Membranes were 
imaged using the LiCor Odyssey system and densitometry performed using the 
Odyssey software (Licor).  
 
Superoxide Dismutase (SOD) Enzyme Activity SOD activity was measured using a 
commercially available kit according to manufacturer’s protocol (#706002, Cayman 
Chemicals). Briefly, brain tissue homogenates were collected and protein values 
measured using the Lowry assay as described above. Supernatant from brain 
homogenates were combined with a tetrazolium salt solution and xanthine oxidase 
then incubated for 20 minutes at room temperature. Absorbance was read at 450nm on 
a Victor microplate reader  (Wallac 1420, Perkin Elmer, Waltham, MA, USA).  
 
Catalase Enzyme Activity Catalase enzyme activity was measured according to 
manufacturer’s protocol (#707002 Cayman Chemicals). Briefly, brain tissue 
homogenates were collected and protein value measured using Lowry assay as 
described above. Supernatant from brain homogenates were combined with hydrogen 
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peroxide for 20 minutes at room temperature before being incubated with potassium 
hydroxide and chromagen for 10 minutes at room temperature. Samples were then 
incubated with potassium periodate for 5 minutes at room temperature. Absorbance 
was measured at 405nm using a Victor microplate reader  (Wallac 1420, Perkin 
Elmer). 
 
Lipid Peroxidation Levels Lipid peroxidation levels were measured using a 
thiobarbituric acid reactive substances (TBARS) commercially available kit according 
to the manufacturer’s protocol (#10009055, Cayman Chemicals). Briefly, brain tissue 
homogenates were collected and protein value measured using Lowry assay as 
described above. Briefly, supernatant from brain homogenates were combined with 
sodium dodecyl sulfate (SDS) and color reagent (thiobarbituric acid, sodium 
hydroxide, and acetic acid) and then boiled for one hour. Samples were placed on ice 
for 10 minutes and centrifuged at 14,000g for 10 minutes. Absorbance was measured 
at 540nm using the SpectraMax microplate reader (190, Molecular Devices, 
Sunnyvale, CA, USA).  
 
Statistical Analyses  
All statistical analyses were performed using the JMP software program (Version 
10.0, SAS Institute, Inc., Cary, NC, USA).  
Multivariate Analysis Behavioral results were analyzed using a multivariate analysis 
of variance (MANOVA), analysis.  
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One-Way Analysis of Variance (ANOVA) One-way ANOVA was performed for all 
analyses. Post-hoc analysis was performed using the Tukey Kramer Honestly 
Significant Difference (HSD) test to compare each treatment group to each other 
(Table 2). 
Table 2. Statistical Comparisons were made between groups in each cell by Tukey 
HSD.  
Tukey Test Comparisons 
Biologically Relevant Comparisons Non-Biologically Relevant Comparisons 
NTG VEH – DTG VEH  NTG VEH  – DTG E2  
NTG VEH – NTG E2  NTG VEH – DTG E2Q  
NTG VEH – NTG E2Q  NTG E2  – DTG E2Q  
NTG E2 – NTG E2Q  NTG E2 – DTG VEH  
NTG E2 – DTG E2   
DTG VEH – DTG E2   
DTG VEH – DTG E2Q   
DTG E2 – DTG E2Q   




Estrogen levels measured by EIA Circulating estradiol levels were measured to 
confirm ovariectomy (OVX) and release of compounds from the osmotic pump as 
previously reported (Chapter 2). We did not attempt to quantify the concentration of 
compound released due to low cross reactivity (<10%) of the estradiol antibody with 
the quinol compound. Results showed that OVX females had low or non-detectable 
estradiol levels, verifying the complete removal of the ovaries. Serum was collected 
at 0, 4, and 8 weeks of treatment. Additionally at sacrifice uterine wet weight was 
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measured as gram weight of the uterine tissue.  Estradiol levels as well as uterine wet 
weight measurement were previously reported in chapter 2.  
 
Complex III and IV protein levels increased in OVX E2Q treated females Protein 
levels of the five electron transport chain complexes (I-V) were measured in intact and 
OVX females (Figure 3.2). In the intact treated females, NTG females had an increase 
in complexes III protein levels in the E2 treated group (p = 0.0008) and E2Q treated 
group (p = 0.0009) as compared to the vehicle control (Figure 3.1).  Additionally there 
was an increase in complex II protein levels in the intact E2Q treated group as 
compare to the vehicle treated group (p = 0.0004) and the E2 treated group (p = 
0.0005) (Figure 3.1). In the OVX treatment groups there was an increase in complex 
III protein levels in the DTG E2Q treated groups compared to the vehicle treated 
group (p = 0.0045) and the E2 treated group (p = 0.0054) (Figure 3.2). Additionally, 
there were increased complex IV protein levels in both the NTG and DTG E2Q treated 
groups as compared to the vehicle controls (NTG, p < 0.0001, DTG p < 0.0001) and 
the E2 (NTG, p < 0.0001, DTG, p < 0.0001) treatment groups (Figure 3.2).  
 
Lipid peroxidation (TBARS) Measurement of lipid peroxidation using the TBARS 
assay showed a significant increase in the NTG OVX E2Q treated group as compared 
to the NTG OVX vehicle group (p = 0.0081) (Figure 3.3). However the DTG OVX 
E2Q treated group were not significantly different as compared to the vehicle DTG 




Superoxide dismutase activity was not altered in treated females Total superoxide 
dismutase (SOD) activity was measured using supernatant collected from brain 
homogenates (Figure 3.4). There were no observable differences in the levels of SOD 
in either the intact treated females. Interestingly, the DTG OVX females showed 
significantly lower (p = 0.0276) SOD levels in the vehicle and E2 treatment groups as 
compared to the NTG OVX E2 treatment groups (Figure 3.4).  
 
Catalase activity Catalase (CAT) activity and was measured in supernatant collected 
from brain homogenates. No significant differences were observed among all 
treatment groups for the CAT activity levels (Figured 3.5).  
 
Discussion 
Release and Effects of E2Q As was determined in our previous study (Chapter 2) 
there was sufficient E2Q measured in the plasma samples from treated females to 
demonstrate effective release of the compound from the minipumps. Additionally, it 
was previously reported that uterine tissue was not stimulated by the E2Q compound 
(Chapter 2). This confirms previous research (Prokai, Personal Communication) 
showing little or no stimulation of peripheral steroid sensitive tissues by E2Q. No 
adverse effects were observed throughout the duration of the study. 
 
ETC Protein Complex Levels Vary In the intact treated females, NTG females had 
an increase in protein complexes II and III when comparing the vehicle and E2Q 
treated groups. This is interesting, since compared to the DTG intact females the NTG 
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intact females did have significantly lower levels of complexes II and III.  In the OVX 
treatment groups there was an increase in protein complexes III and IV when 
comparing the E2 and E2Q treatment groups in both the NTG and DTG genotype. The 
increase of complex IV may be beneficial in humans with AD, since studies have 
demonstrated deceased levels of complex IV protein in the AD population (Cardoso 
2004). Additionally, it should be noted that complex II is not a know site of ROS 
production, and thus changes in the availability of these complexes should not increase 
ROS production capabilities of the mitochondria.  
 
Lipid Peroxidation (TBARS) Lipid peroxidation is a measurement of macromolecule 
oxidation due to reactive oxygen species (ROS). The amount of lipid peroxidation, is 
related to the formation of malondialdehyde acid (MDA) in the assay we used. MDA 
formation increased in the NTG E2Q OVX female group and this could be due to a 
lack of endogenous estrogens. Since the E2Q doesn’t act like estrogen until it is 
metabolized in the system, the lack of endogenous estrogen could leave the system 
vulnerable to increased ROS. 
 
SOD Activity Total superoxide dismutase (SOD) activity was measured in 
supernatants collected from brain homogenates. In the NTG animals we did not 
observe any differences in the levels of SOD in either the intact or OVX treated 
females.  Interestingly, the DTG OVX females showed significantly lower SOD levels 
in the vehicle and E2 treatment groups as compared to the NTG OVX E2 treatment 
groups. Previous studies have determined that in humans with AD, cytosolic 
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Cu/ZnSOD was increased at the protein level, but no change was observed at the 
activity level (Puertas 2012). While our assay measured total SOD, a difference may 
likely exist between Cu/ZnSOD and MnSOD. Mitochondrial MnSOD activity and 
protein level of MnSOD would be an important test that could elucidate any 
differences between cytosolic and mitochondrial changes in AD. Additionally, total 
SOD and Cu/ZnSOD protein levels should be measured as well to determine if the 
amount of enzyme available is different among treatment groups. 
 
CAT Activity Catalase (CAT) activity overall did not show any significant differences 
among treatment groups.  However, assessment of total CAT protein levels could be 
beneficial because while the enzyme activity was not different, this could be due to the 
amount of CAT protein available to the system. Other research has shown that changes 
in activity and protein level vary in AD patients, and thus both aspects should be 
considered (Puertas 2012).  
 
 In summary, the E2 and E2Q treatments appeared to be beneficial for a number of 
endpoints relating to oxidative damage and mitochondrial function. The increase of 
protein complex IV levels in the OVX E2 and E2Q treated females could be extremely 
beneficial in regards to humans with AD since there was decrease level of the complex 
IV protein in the AD population (Cardoso 2004). Additionally, the increase of protein 
complex IV in the OVX AD system is a positive result since this demonstrates that 
OVX insult can be overcome in some aspects with the E2 or E2Q treatments. However 
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Chapter 4: EFFICACY OF AN ESTROGEN PRO-DRUG IN MALES: STUDIES 
IN A MURINE MODEL OF ALZHEIMER’S DISEASE 
 
Introduction  
Alzheimer’s disease is characterized by cognitive and neuronal dysfunction 
associated with Amyloid-Beta (Aβ) plaques and neurofibrillary tangles (NFTs). Age 
is the leading risk factor for the development of sporadic AD, however genetic 
mutations, as in the case of Familial Alzheimer’s Disease (FAD), increase a person’s 
chance of developing AD (Goate 1991, Kamino 1992, Mullan 1992,). These human 
genetic variants have been used to create animal models enabling further study of the 
pathology of AD. In this study we used an AD double-transgenic mouse (DTG) 
model of early onset human AD. This DTG mouse strain possesses a chimeric 
mouse/human APP Swedish gene (APP695SWE) as well as the human PS1 delta-E-9 
(PS1dE9) gene (Jankowsky 2004). This particular model displays behavioral 
deficiencies at 7 months of age (Reiserer et al., 2007), that correlate temporally with 
the appearance of plaques (Jankowsky 2004). Here we utilized an estrogen pro-drug, 
E2-Quinol as a potential therapeutic within the DTG mouse model.  
 
Estrogen and Neuroprotection in Males It has been established that females develop 
Alzheimer’s disease more often than males (Andersen 1999, Lobo 2000, Callahan 
2001, Irvine 2012). Evidence supports the contention that estrogen hormones  provide 
neuroprotection within the brain (Brinton 2001 and Simpkins 2012); however 
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peripheral effects, including stimulation of estrogen-sensitive cancer and exacerbation 
of risk for stroke and heart disease have diminished their clinical use as a therapeutic. 
Estrogens act on several targets including direct estrogen receptor activation of the 
MAPK/ERK pathway as well as the non-receptor mediated antioxidant activity of 
estrogen (Brinton 2001 and Simpkins 2012) thereby offering neuroprotection. 
Researchers know that estrogen treatments up-regulate expression of genes that are 
themselves protective or associated with neuronal survival such as bcl-2, 
CaMKIIα(+), and Jak1 and 2(+ and -) (Manthey and Behl). Additionally estrogen 
receptor alpha and beta (ERα/β) sub-types can positively and negatively influence 
gene regulation of APP, PS1, and ADAM10, genes affiliated with AD (Manthey and 
Behl). This suggests not only a potential gene level effect, but also points to how 
different receptor subtypes may alter gene expression. Badeau and colleagues (2005) 
demonstrated that the antioxidant property of estrogenic compounds is due to the free 
phenolic hydroxyl group found on the A-ring of the steroid. 
 Thus far, the effect of estradiol in human populations has been focused around 
menopausal women. However, estrogen therapies in men are an important area of 
research showing promising results. Researchers have shown that in a triple 
transgenic AD mouse model (3xTgAD), gonadexctomized males (GDX) treated with 
E2 prevented Aβ accumulation seen in the GDX mice (Rosario 2010). These data 
provide rationale to believe E2 might be equally beneficial in males and these studies 




Purpose In the present study we assessed the effect of E2-Quinol (E2Q), a pro-drug 
in males of a DTG mouse model.  The development of E2Q has allowed for the study 
of a new class of estradiol pro-drug therapeutics (Laszlo 2001). As a pro-drug, E2Q, 
enters the system in the quinol form and is metabolized through NADPH reductase, 
into estrogen. This metabolism occurs in the brain at a rate 200x faster than in the 
body (Gleason 2006). This high rate of metabolism allows for more of the estrogen 
parent compound to accumulate in the brain than in the body. The purpose of this 
study was to determine the effect of E2Q on behavioral, biochemical, and 
mitochondrial endpoints in a DTG AD mouse model. We measured behavior, APP 
and Aβ protein levels, plaque load, electron transport chain protein complex (I-V) 
levels, superoxide dismutase activity, catalase activity, and lipid peroxidation. This 
study was performed in intact males. We report the E2Q treated males made less 
errors compared to the vehicle treated males and had lower levels of APP and Aβ 
protein levels. Additionally mitochondrial complex proteins I, II and IV were altered 
with E2 and E2Q treatment.  
 
Materials and Methods 
Synthesis and Characterization of E2-quinol Compound Estrogen-derived para-quinol 
17β-dihydroxyestra-1,4-diene-3-one (E2-quinol, E2Q) was synthesized from estradiol 
(E2), as previously reported (Prokai 2000). Briefly, a stirred solution of estradiol (E2, 
190mg, E8875, Sigma-Aldrich, St. Louis, MO, USA), 3-chloroperbenzoic acid (m-
CPBA, 273031, Sigma-Aldrich), and Benzoyl peroxide (PhCO)2O2, 33581, Sigma-
Aldrich) in 40-60 ml dry carbon tetrachloride/Me2CO (CCl4/Me2CO, 4:1 v/v) was 
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heated to reflux while irradiated with 60 W tungsten lamp (Solaja 1996). Reaction 
completion was verified by thin layer chromatography. The residue was dissolved in 
CHCl3 and washed with saturated NaHCO3 to remove m-chlorobenzoic acid; the 
organic phase was evaporated and the remaining residue was divided into several 
portions to ensure manageability and then purified by column chromatography on 
silicagel. For purification the column was washed extensively with dichloromethane 
to remove any residual E2 followed by elution of E2Q with 
ethylacetate/dichloromethane mixture (CH3COOCH2CH3/CH2Cl2, 9:1, v/v). The 
purity of the compound (white solid) was verified by high performance liquid 
chromatography (HPLC), liquid chromatography/mass spectrometry (LC/MS) and 
gas chromatography/mass spectrometry (GC/MS). Purity of the final product was 
>99% with no trace amounts of the starting material.  
 
Animal Husbandry Transgenic APPswe/PS1dE9 (B6.Cg-Tg (APPswe, 
PSEN1dE9)85Dbo/J,   Jackson Labs, Bar Harbor, ME, USA)  mice were obtained at 
3-4 months of age from the colony of Dr. Rosemary Schuh maintained at the 
Veterans Affairs Maryland Health Care System (Baltimore, MD). Animals were 
received and transferred following IACUC approved protocols. The APPswe/PS1dE9 
hemizygote genotype was maintained by crossing a female wild-type (C57BL/6, 
000664, Jackson Labs, Bar Harbor, ME, USA) with a male APPswe/PS1dE9.  
Animals were purchased, bred on site and weaned at 21-25 days of age and then tail 
snipped and genotyped at 30-35 days of age. Animals were group housed by gender 
in an environmentally controlled animal facility on a 12-hour light/dark schedule. 
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Food and water were provided ad libitum at the University of Maryland College Park. 
All animal care and experimental procedures were conducted under the University of 
Maryland, College Park Institutional Animal Use and Care Committee (IACUC) 
approved protocols. To minimize any confounding factor of estrogenic compounds in 
the diet, one week prior to experimental treatment animals were placed on a 
phytoestrogen free diet (AIN-93G, Bio-Serv, Frenchtown, NJ, USA) to eliminate 




Treatment Groups Male APPswe/PS1dE9 mice (5.5-6 months) were treated with 
vehicle (propylene glycol, P4347, Sigma), E2 (2ug/day), or E2-quinol (2ug/day) (N = 
7-9). Due to the long ½ life of the quinol compound in the body, the Alzet osmotic 
minipumps (2004, 0.25ul/min, Durect Corp., Cupertino, CA) were used to deliver the 
appropriate dose over the 8 week period of treatment. Pumps were replaced once, at 
the 4 week time point.  Compounds were dissolved in USP-grade propylene glycol, a 
substance in which both estrogen and the E-quinol compound are freely soluble and 
which is compatible with Alzet pumps. Animals were lightly anesthetized using 
isoflurane at an appropriate dose for mice according to the AALAS recommendation. 
After anesthetization, a small patch of hair was removed from the upper back of the 
mouse and the area disinfected. A small incision was made on the operative area and 
the Alzet osmotic pump implanted subcutaneously between the scapulae. The incision 
was closed, sutured and allowed to heal. Following surgery, animals recovered on a 
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surgical grade (DCT-15, Kent Scientific Instruments, Torrington, CT) heating pad 
under continuous observation before being placed in a cage containing clean, dry 
bedding, atop a heating pad. No special post-operative care was generally required. 
Animals were monitored daily for possible infection and to ensure wounds remained 
clean, the animal maintained a healthy body weight, and there were no adverse 
effects.  
Table 4.1. Treatments and number of males in each treatment group 
  NTG DTG 
Vehicle 8 8 
E2 (2ug/day) 9 7 
E2-Quinol (2ug/day) 9 9 
 
Estrogen Measurements 
Estradiol EIA An estradiol (E2) EIA 17β-Estradiol kit (582251, Cayman chemicals, 
Ann Arbor, MI, USA) was validated and used to measure estradiol in serum samples 
as previously reported (Chapter 2).  
 
Radial Arm Water Maze (RAWM) Behavioral Testing A radial-arm water maze 
(Alamed 2006) was used to measure cognitive deficits of the mice post-treatment 
period. The details of this paradigm were previously reported (Chapter 2).  
 
Tissue Collection Following RAWM protocol animals were euthanized by cervical 
dislocation. Brain was immediately removed and half of each brain was flash frozen 
for storage at -80C. For analysis, the brain sample was homogenized using 1ml of 
homogenization buffer (225mM ultra pure mannitol, 75mM ultra pure sucrose, 5mM 
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Hepes, 1mM EGTA, pH to 7.4 at 4˚C, Sigma). Homogenate protein levels were 
measured using the standard Lowry protein assay (Protein Assay Reagent A (500-
0113) and Protein Assay Reagent B (500-0114), Bio-Rad, Hercules, CA, USA) 
(Lowry 1951). The other half of each brain was post-fixed in 4% paraformaldehyde 
and transferred to 30% sucrose after 24 hours. Tissue was allowed to sink in the 




Western Blot for APP Protein levels were measured on the brain homogenates by 
Western blot analysis. Western blots were performed using a 10% Bis-Tris gel (456-
1046,Bio-Rad) and samples were normalized to 25ug protein. Briefly, samples were 
boiled at 95 °C for 15 minutes in the presence of loading buffer ((25ul) Beta-
Mercaptoethanol M6250 Sigma and (475ul) Laemmli Buffer 161-0737, Bio-Rad), 
vortexed and spun down before being loaded onto the gel. Samples were processed 
through the gel at 200v for 30 minutes. Gels were then transferred to an Immobilon 
FL PVDF membrane (IPFL00010, Millipore, Billerica, MA, USA) using the transblot 
transfer system (170-4155, Bio-Rad) at 2.5A, 10v for 10 minutes. Membranes were 
blocked ((60 min) 927-40000, LiCor) before being exposed to primary antibodies 
against amyloid precursor protein (6E10, 39340, Covance, Princeton, NJ, USA) and 
the housekeeping protein beta-actin (4967, Cell Signaling, Danvers, MA, USA) 
overnight at 4C. Membranes were then exposed to secondary anti-mouse (6E10) and 
anti-rabbit (beta-actin) iRdye antibodies (827-08366 and 926-32211, LiCor, Lincoln, 
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NE, USA). Membranes were imaged using the LiCor Odyssey system and 
densitometry performed using the Odyssey software (Licor, Lincoln, NE, USA).  
 
Amyloid Beta ELISA Aβ1-40 and Aβ1-42 variants were quantified using commercially 
available ELISA kit ((40) KHB3481 and (42) KHB3441, Invitrogen, Grand Island, 
NY, USA). Briefly, standards provided by the company, and samples were measured 
using a monoclonal primary (rabbit) antibody specific for the NH2-terminus region of 
Human Aβ 1-40 or 1-42. The bound primary antibody was detected with the use of a 
horseradish peroxidase-labeled anti-rabbit antibody. Finally a stabilized chromagen 
solution was added which causes a color change directly proportional to the amount of 
Human Aβ present in the sample. Absorbance was measured at 450nm using the 
Victor microplate reader (Wallac 1420, Perkin Elmer, Waltham, MA, USA). Final 
concentration values of Aβ were calculated as pg/mg.  
 
Western Blot for OxPhos Complex I-V Protein levels were measured on the brain 
homogenates by Western blot analysis. Western blots were performed using a 10% 
Bis-Tris gel (456-1046,Bio-Rad, Hercules, CA, USA) and samples were normalized 
to 25ug protein. Briefly, samples were boiled at 95 °C for 15 minutes in the presence 
of loading buffer ((25ul) Beta-Mercaptoethanol M6250 Sigma and (475ul) Laemmli 
Buffer 161-0737, Bio-Rad), vortexed and spun down before being loaded onto the 
gel. Samples were processed through the gel at 200v for 30 minutes. Gels were then 
transferred to an Immobilon FL PVDF membrane (IPFL00010, Millipore, Billerica, 
MA, USA) using the transblot transfer system (170-4155, Bio-Rad) at 2.5A, 10v for 
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10 minutes. Membranes were blocked ((60 min) 927-40000, LiCor) before being 
exposed to primary antibodies against complexes I-V (OxPhos Cocktail, MS604, 
Mitosciences, Eugene, OR, USA) and the housekeeping protein beta-actin (4967, Cell 
Signaling, Danvers, MA, USA). Membranes were then exposed to secondary anti-
mouse (OxPhos) and anti-rabbit (beta-actin) iRdye antibodies (827-08366 and 926-
32211, LiCor). Membranes were imaged using the LiCor Odyssey system and 
densitometry performed using the Odyssey software (Licor).  
 
Superoxide Dismutase (SOD) Enzyme Activity SOD activity was measured using a 
commercially available kit (706002, Cayman Chemicals). Briefly, tissue homogenates 
were collected and protein value measured using Lowry assay as described above. 
Homogenate supernatant was combined with a tetrazolium salt solution and xanthine 
oxidase and allowed to incubate for 20 minutes at room temperature. Absorbance was 
read at 450nm on a Victor microplate reader  (Wallac 1420, Perkin Elmer).  
 
Catalase Enzyme Activity Catalase enzyme activity was measured according to 
manufacturer’s protocol (#707002 Cayman Chemicals). Briefly, tissue homogenates 
were collected and protein value measured using Lowry assay as described above. 
Homogenate supernatant was combined with hydrogen peroxide for 20 minutes at 
room temperature before being incubated with potassium hydroxide and chromagen 
for 10 minutes at room temperature. Finally samples were incubated with potassium 
periodate for 5 minutes at room temperature. Absorbance was measured at 405nm 




Lipid Peroxidation Levels Lipid peroxidation levels were measured using a 
commercially available kit (10009055, Cayman Chemicals). Briefly, tissue 
homogenates were collected and protein value measured using Lowry assay as 
described above. Briefly, homogenate supernatant was combined with sodium dodecyl 
sulfate (SDS) and Color reagent (thiobarbituric acid, sodium hydroxide, and acetic 
acid) and boiled for one hour. Samples were then placed on ice for 10 minutes and 
centrifuged at 14,000g for 10 minutes. Absorbance was measured at 540nm using the 
SpectraMax microplate reader (190, Molecular Devices, Sunnyvale, CA, USA).  
 
 
Statistical Analyses  
All statistical analyses were performed using the JMP software program (Version 
10.0, SAS Institute, Inc., Cary, NC, USA).  
Multivariate Analysis Behavioral results were analyzed using a multivariate, 
MANOVA, analysis.  
One-Way ANOVA One-way ANOVA was performed for all analyses. Post-hoc 
analysis was performed using the Tukey Kramer HSD test to compare each treatment 
group to each other (Table 2). 
Table 4.2. Statistical Comparisons were made between groups in each cell by Tukey 
HSD.  
Tukey Test Comparisons 
Biologically Relevant Comparisons Non-Biologically Relevant Comparisons 
NTG VEH – DTG VEH  NTG VEH  – DTG E2  
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NTG VEH – NTG E2  NTG VEH – DTG E2Q  
NTG VEH – NTG E2Q  NTG E2  – DTG E2Q  
NTG E2 – NTG E2Q  NTG E2 – DTG VEH  
NTG E2 – DTG E2   
DTG VEH – DTG E2   
DTG VEH – DTG E2Q   
DTG E2 – DTG E2Q   
DTG E2Q – NTG E2Q   
 
Results 
Estrogen levels measured by EIA Circulating estradiol levels were measured to 
confirm release of compounds from the osmotic pump (Figure 4.1). We did not 
attempt to quantify the concentration of compound released due to low cross 
reactivity (<10%) of the estradiol antibody with the quinol compound. Results 
showed that males had low or non-detectable estradiol levels at week 0. Serum was 
collected at 0, 4, and 8 weeks of treatment. The males receiving the vehicle did not 
have detectable levels of estrogen at 4 weeks of treatment as compared to intact 
vehicle treated males (NTG p < 0.0001, DTG p < 0.0001) as well as at 8 weeks of 
treatment (NTG p < 0.0001, DTG p < 0.0001) (Figure 4.1). Males receiving E2 or 
E2Q had detectable levels of estrogen at 4 weeks (NTG p < 0.0001, DTG p < 0.0001) 
as well as 8 weeks of treatment (NTG p < 0.0001, DTG p < 0.0001) (Figure 4.1). 
Additionally, while E2 and E2Q treated males did not significantly differ from each 
other at 4 weeks, the E2Q treated males had significantly higher levels of estrogen at 
8 weeks of treatment (p = 0.0029) (Figure 4.1).  
 
RAWM behavioral testing Initial differences in errors and latency between the NTG 
and DTG vehicle treated groups were observed. On day 1 the NTG vehicle treated 
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group performed significantly less errors than the DTG vehicle treated group (p = 
0.0460)(Figure 4.2). Interestingly, the DTG E2Q treated group performed fewer 
errors than the DTG vehicle treated group (p = 0.0064) and the DTG E2 treated group 
(p = 0.0006)(Figure 4.2). On day 2 of testing the DTG E2Q treated group again 
performed better than the DTG vehicle treated group (p = 0.0056) as well as the DTG 
E2 treated group (p = 0.0030) (Figure 4.2). On day 3 of testing the DTG E2Q treated 
group again performed better than the DTG vehicle treated group (p = 0.0001) and 
the DTG E2 treated group (p = 0.0242)(Figure 4.2). Additionally, the DTG E2Q 
treated group was not significantly different from all NTG treated groups. 
 
APP protein levels The DTG vehicle treated group had significantly higher levels of 
full length APP compared to the NTG vehicle treated group (p = 0.0142) (Figure 4.3). 
However, the APP levels were significantly decreased in both the DTG E2 treated 
group (p = 0.0065) and also in the DTG E2Q treated group (p =0.0195)(Figure 4.3). 
DTG E2 and E2Q treated groups did not differ significantly from any of the NTG 
treatment groups (representative image Chapter 2).  
 
Reduced Aβ Levels Aβ levels were measured for the 1-40 and 1-42 variants.  Across 
groups there were no significant differences in the amount of Aβ 1-40 (Figure 4.4). 
However, the DTG vehicle treated group had significantly higher levels of Aβ 1-42 as 
compared to DTG E2 treated (p < 0.0001) and DTG E2Q treated (p < 0.0001) groups. 





Superoxide dismutase (SOD), Catalase (CAT) activity, and lipid peroxidation (TBARS) 
did not change SOD (Figure 4.6) and CAT (Figure 4.7) activity were not significantly 
different across treatment groups. Additionally no differences were observed for the 
measure of lipid peroxidation using the TBARS endpoint (Figure 4.5).   
 
ETC complex protein levels Protein levels of the five electron transport chain 
complexes (I-V) were measured in male brain homogenates (Figure 4.8). There was a 
significant increase in the protein levels of complex I (p = 0.0079), complex II (p < 
0.0001) and complex IV (p = 0.0087) in the DTG vehicle treatment group as compared 
to the DTG E2Q treated group (Figure 4.8). Additionally the level of complex IV 
protein in the DTG E2 and E2Q treated groups did not significantly differ from any of 
the NTG treated groups (Figure 4.8) (representative image Chapter 3).  
 
Discussion  
Estrogen levels show delivery of compound Our assay did not detect baseline levels 
of estrogen in males. Males receiving E2 or E2Q had detectable levels of estrogen at 
4 weeks and 8 weeks of treatment, which confirms the delivery of the compound. E2 
and E2Q treated males did not significantly differ from each other at 4 weeks, 
however the E2Q treated males had higher levels of estrogen at 8 weeks of treatment. 
This is interesting and may have to do with a difference of the metabolism of the E2Q 




Cognitive benefits seen in behavioral testing Initial differences in errors between 
the NTG and DTG vehicle treated groups were rescued in the E2 and E2Q treated 
groups by day 3 of testing. Additionally, the DTG E2Q treated group performed 
fewer errors the DTG E2 treated group as well as the vehicle treated group, indicating 
the E2Q treatment provided more benefit than the E2.  
 
APP levels decreased with E2 and E2Q treatment Initially we saw the expected 
difference between the NTG and DTG vehicle treated groups; the DTG vehicle group 
had significantly higher levels of APP compared to the NTG vehicle treated group. 
However, with E2 treatment the APP levels of the DTG group decreased, as did the 
APP levels of the DTG E2Q treated group. DTG E2 and E2Q treated groups did not 
differ significantly from each other or any of the NTG treatment groups. This 
indicates the E2 as well as the E2Q were able to bring the level of APP protein in the 
system down to a level equal to that of the NTG animals. This could provide 
tremendous benefits in the way of reducing overall APP in patients who carry genes 
causing them to overexpress APP. However, caution is needed due to the endogenous 
activity of APP relating to synaptogenesis and synaptic plasticity; reducing APP too 
much could also be a problem.  
 
Aβ levels were reduced in E2 and E2Q treated groups Across groups there were 
no significant differences in the amount of Aβ 1-40, which indicates that in the males 
of the DTG model, E2 and E2Q were not effective at decreasing Aβ 1-40. However, 
the DTG vehicle treated group had significantly higher levels of Aβ 1-42 as compared 
 78 
 
to DTG E2 treated DTG E2Q treated groups. Therefore, E2 and E2Q were effective at 
decreasing Aβ 1-42. Since Aβ 1-42 is the more hydrophobic, and thus plaque 
forming, form of Aβ this is a great benefit to the animals. By decreasing overall levels 
of Aβ E2 as well as E2Q could potentially minimize the amount of senile plaques 
formed. It follows that we have decreased APP and thus have decreased Aβ, however 
there is also the possibility for the E2 or E2Q to be effecting formation of Aβ 1-42 
through a different pathway. 
 
ETC complex I, II, and IV protein levels increased Protein levels of the five 
electron transport chain complexes (I-V) were measured in treated males. Our data 
showed an increase with E2Q treatment of protein complexes I, II and IV. The 
increase in all these protein levels could be beneficial to the cellular respiration of the 
cell, thus increasing overall cell viability. Specifically, complex IV is seen in the 
human literature to be deficient in AD patients, and thus increasing the amount of this 
protein could be a great benefit to the overall health of their mitochondrial system.  
 
No differences seen in SOD or CAT activity levels No differences were observed in 
the SOD or CAT enzyme activity levels across treatment groups. While this assay 
measured total SOD, a difference may likely exist between Cu/ZnSOD and MnSOD. 
Cu/ZnSOD is cytosolic while MnSOD is specific to mitochondria so looking at the 
activity and level of MnSOD would be an important test that could elucidate any 
differences in activity of cytosolic versus mitochondrial SOD. Additionally, total 
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CAT, SOD, Cu/ZnSOD, and MnSOD enzyme protein levels should be measured to 
determine if the amount of enzyme available differs among treatment groups.  
 
TBARS levels were not affected TBARS, the measure of lipid peroxidation we used, 
did not show any differences among treatment groups. Lipid peroxidation is associated 
with an increased level of ROS in a system. While there is a trend in our data of a 
higher level of TBARS in the DTG vehicle treated group and a decrease with E2Q 
treatment, these data were not significant. This may be due to an overall lower level of 
ROS present in males. Alternatively, this lack of significance is likely due to the large 
variance within our groups and increasing the number of animals per group may 
elucidate significant difference. 
 
In summary, the behavioral responses seen in the males is promising because these 
data show the E2Q	   compound	   may	   beneficial	   for	   males	   as	   well	   as	   females	   for	  
whom	   E2Q	   provided	   a	   behavioral	   benefit	   as	   previously	   reported	   (Chapter	   2).	  
Additionally,	   the	   reduction	  of	  Aβ	   fragments,	   as	  well	   as	  APP	  as	  a	   result	  of	  E2	  or	  
E2Q	  treatment	  indicates	  E2Q	  is	  acting	  in	  manner	  similar	  to	  that	  of	  E2,	  and	  may	  be	  
acting	  through	  the	  same	  mechanisms	  as	  E2.	  	  It	  has	  been	  shown	  that	  Aβ	  release	  is	  
activity	  dependent	  (Cirrito	  2008)	  and	  so	  it	  would	  interesting	  to	  explore	  possible	  
correlations	   that	   may	   exist	   between	   behavioral	   benefit	   and	   reduction	   of	   Aβ	  
fragments.	   	   Regarding	   mitochondrial	   changes,	   the	   lack	   of	   many	   significant	  
changes	  is	  disappointing,	  however	  as	  discussed	  other	  measurements	  may	  give	  us	  
further	   insight	   into	   the	   mechanisms	   of	   E2Q.	   	   One	   promising	   finding	   was	   the	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increase	  of	  complex	  IV,	  which	  is	  often	  deficient	  in	  AD	  patients,	  and	  a	  therapeutic	  
which	   increases	   this	   protein	   may	   be	   beneficial	   to	   mitochondrial	   respiration.	  
Overall,	   the	   behavioral	   benefit	   and	   Aβ	   fragment	   changes	   are	   promising	   and	  















































































Chapter 5:  EFFICACY OF AN ESTROGEN PRO-DRUG IN A TRIPLE 
TRANSGENIC MURINE MODEL OF ALZHEMER’S DISEASE 
 
Introduction 
 Alzheimer’s disease (AD) is characterized by cognitive and neuronal 
dysfunction associated with Amyloid-Beta (Aβ) plaques and neurofibrillary tangles 
(NFTs). Age is the leading risk factor for the development of sporadic AD, however 
genetic mutations can increase a person’s chance of developing AD (Goate 1991, 
Kamino 1992, Mullan 1992). Some of these genetic variants have been used to create 
animal models enabling further study of the pathology of AD. In this study we used a 
triple-transgenic mouse (3xTgAD) model of early onset AD. The 3xTgAD model 
possesses three of the human genes for AD; APP Swedish (APPSWE), PS1 M146V 
(PS1M146V), and Tau (TauP301L) (Oddo 2003). This particular strain displays 
behavioral deficiencies at 12 months of age that correlate temporally with the 
appearance of amyloid plaques and neurofibrillary tangles.  
 Researchers have demonstrated the effect of estrogen within this 3xTgAD 
mouse model (Chen 2011, Rosario 2012). Estrogens provide various routes of 
neuroprotection such as direct estrogen receptor activation of the mitogen activated 
protein kinase/extracellular signal-related kinase (MAPK/ERK) pathway and non-
receptor mediated antioxidant activity (Brinton 2001; Simpkins 2012). This 
antioxidant characteristic is due to the free phenolic hydroxyl group found on the A-
ring of estradiol (Badeau 2005). Estrogen treatment has shown to up-regulate genes 
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associated with neuronal survival such as bcl-2(+), IGFBP-5(+), Calmodulin(+), 
CaMKIIα(+), Mef2C(+), Connexin43(-), and Jak1 and 2(+ and -)(Manthey and Behl 
2006). Additionally, Manthey and Behl identified that ERα and β receptor transfected 
cells can positively and negatively regulate genes affiliated with AD such as APP(-), 
PS1(+ and -), and ADAM10(+) (Manthey and Behl, 2006).  Other hormones have 
shown promise as therapeutics in the 3xTgAD model; Allopregnanolone increased 
the number of BrdU labeled cells (a measure of new cells) and decreased 6E10 
staining in the hippocampus of the 3xTg mouse model of AD (3xTgAD)(Chen 2011). 
Additionally, testosterone reduced AD pathology in the triple transgenic mouse 
model (Rosario 2012). Gonadectomized (GDX) male 3xTgAD mice, testosterone 
treatment at the time of GDX prevented a plaque load increase seen with GDX mice 
(Rosario 2012). These data taken together provide strong evidence for hormone 
therapeutics to deliver benefits within the 3xTgAD model.  
  The E2-Quinol (E2Q) pro-drug has allowed for the study of a new class of 
estradiol pro-drug therapeutics (Laszlo 2001). E2Q, as a pro-drug, enters the system 
in the quinol form and is metabolized through NADPH reductase, into estrogen. This 
metabolism occurs in the brain at a rate 200x faster than in the body (Gleason 2006). 
This high rate of metabolism in the brain leaves more of the estrogen parent 
compound in the brain allowing for diminished negative peripheral effects.  
 The effects of E2Q treatment was investigated in the 3xTgAD model. We 
used the 3XTgAD mouse model because they have different variations of the APP 
and PS1 genes, and they develop plaques and cognitive dysfunction later than other 
mouse models. This study examines the effect of the E2Q pro-drug both 
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ovariectomized and intact animals of the 3xTgAD mouse model of AD.  Specifically, 
we measured the levels estradiol delivered through the treatments, uterine wet weight, 
total protein level of APP, and total protein level of Aβ.  
Materials and Methods 
Synthesis and Characterization of E2-quinol Compound Estrogen-derived para-quinol 
17β-dihydroxyestra-1,4-diene-3-one (E2-quinol, E2Q) was synthesized from estradiol 
(E2), as previously reported (Prokai 2000). Briefly, a stirred solution of estradiol (E2, 
190mg, E8875, Sigma-Aldrich, St. Louis, MO, USA), 3-chloroperbenzoic acid (m-
CPBA, 273031, Sigma-Aldrich, St. Louis, MO, USA), and Benzoyl peroxide 
(PhCO)2O2, 33581, Sigma-Aldrich, St. Louis, MO, USA) in 40-60 ml dry carbon 
tetrachloride/Me2CO (CCl4/Me2CO, 4:1 v/v) was heated to reflux while irradiated 
with 60 W tungsten lamp (Solaja 1996). Reaction completion was verified by thin 
layer chromatography. The residue was dissolved in CHCl3 and washed with 
saturated NaHCO3 to remove m-chlorobenzoic acid; the organic phase was 
evaporated and the remaining residue was divided into several portions to ensure 
manageability and then purified by column chromatography on silicagel. For 
purification the column was washed extensively with dichloromethane to remove any 
residual E2 followed by elution of E2Q with ethylacetate/dichloromethane mixture 
(CH3COOCH2CH3/CH2Cl2, 9:1, v/v). The purity of the compound (white solid) was 
verified by high performance liquid chromatography (HPLC), liquid 
chromatography/mass spectrometry (LC/MS) and gas chromatography/mass 
spectrometry (GC/MS). Purity of the final product was >99% with no trace amounts 




Animal Husbandry Triple-transgenic mice (3xTgAD) were rederived at the National 
Institutes of Aging (NIA, Baltimore, MD, USA) from the colony of Dr. Mark 
Mattson. Mice were received at 3-4 months of age and transferred following IACUC 
approved protocols. Animals were bred on site (3xTgAD x 3xTgAD), weaned at 21-
25 days of age and tail snipped and genotyped at 30-35 days of age. Animals were 
group housed by gender in an environmentally controlled animal facility on a 12-hour 
light/dark schedule. Food and water were provided ad libitum at the University of 
Maryland College Park. All animal care and experimental procedures were conducted 
under the University of Maryland, College Park Institutional Animal Use and Care 
Committee (IACUC) approved protocols. To minimize any confounds due to 
estrogenic compounds in the diet, one week prior to experimental treatment animals 
were placed on a phytoestrogen free diet (AIN-93G, Bio-Serv, Frenchtown, NJ). 
Following surgical procedures animals were individually housed. 
 
Experimental Design 
Treatment Groups Male and female 3xTgAD mice (11.5-12 months) were used for 
this study to compare the different hormone profiles in intact animals of the same 
transgenic background. Animals were treated with vehicle (propylene glycol, P4347, 
Sigma, St. Louis, MO), E2 (2ug/day), or E2-quinol (2ug/day) (N = 5). Due to the long 
½ life of the quinol compound in the body, the Alzet osmotic minipumps (2004, 
0.25ul/min, Durect Corp., Cupertino, CA) were used to deliver the appropriate dose 
over the 8 week period of treatment. Pumps were replaced once, at the 4 week time 
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point.  Compounds were dissolved in USP-grade propylene glycol, a substance in 
which both estrogen and the E-quinol compound are freely soluble and which is 
compatible with Alzet pumps. Animals were lightly anesthetized using isoflorane at 
an appropriate dose for mice according to the AALAS recommendation. After 
anesthetization, a small patch of hair was removed from the upper back of the mouse 
and the area disinfected. A small incision was made on the operative area and the 
Alzet osmotic pump implanted subcutaneously between the scapulae. The incision 
was closed, sutured and allowed to heal. Following surgery, animals recovered on a 
surgical grade (DCT-15, Kent Scientific Instruments, Torrington, CT) heating pad 
under continuous observation before being placed in a cage containing clean, dry 
bedding, atop a heating pad. No special post-operative care was generally required. 
Animals were monitored daily for possible infection and to ensure wounds remained 
clean, the animal maintained a healthy body weight, and there were no adverse 
effects. 
 
Table 5.1. Treatments and number of males and females in each treatment group 
 
 
Estradiol EIA Validation An 
estradiol (E2) EIA was validated and 
serum samples were processed as previously reported (Chapter 2).  Uterine wet 




Vehicle 4 5 
E2 (2ug/day) 5 5 
E2-Quinol (2ug/day) 5 5 
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Tissue Collection Following Animals were euthanized by cervical dislocation. Brain 
was immediately removed and half of each brain was flash frozen for storage at -80C. 
For analysis, the brain sample was homogenized using 1ml of homogenization buffer 
(225mM ultra pure mannitol, 75mM ultra pure sucrose, 5mM Hepes, 1mM EGTA, 
pH to 7.4 at 4˚C, Sigma-Aldrich, St. Louis, MO, USA). Homogenate protein levels 
were measured using the standard Lowry protein assay (Protein Assay Reagent A 
(500-0113) and Protein Assay Reagent B (500-0114), Bio-Rad, Hercules, CA, USA). 
The other half of each brain was post-fixed in 4% paraformaldehyde and transferred 
to 30% sucrose after 24 hours. Tissue was allowed to sink in the sucrose solution 
ensuring full saturation of the tissue before being processed for histology.  
 
Histology 
Processing and Immunochemistry for APP Serial sections of 50um thickness were 
collected using a freezing microtome (860, American Optical AO, Buffalo, NY, 
USA) and sections stored in cryobuffer (30% Sucrose (S5-3, Fisher Scientific, Fair 
Lawn, NJ, USA) 1% Polyvinylpyrrolidone (BP431, Fisher Scientific) 30% Ethylene 
Glycol (102466, Sigma-Aldrich, St. Louis, MO, USA) until staining was performed. 
Tissue was washed in 1x TBS to remove cryobuffer residue and treated with 1% 
hydrogen peroxide (H2O2) (30 min, 325-100, Fisher Scientific) to block endogenous 
peroxidase activity. Tissue was then washed again in 1x TBS and treated with 0.3% 
Triton X-100 (10min, BP151, Fisher Scientific, Fair Lawn, NJ, USA) followed by 5% 
Normal Goat Serum (NGS) (30 min, S-1000, Vector Labs, Burlingame, CA, USA). 
Tissue was then exposed to the primary antibody overnight at 4C while on a shaker. 
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Amyloid isoforms and soluble APP were identified using antibodies against APP 
(6E10) (1:300, 39340, Covance, Princeton, NJ, USA). Tissue was then washed and 
treated with the Vectastain ABC kit (90 min, PK-6100, Vector Labs, Burlingame, 
CA, USA), washed again, and exposed to the secondary antibody (90min, 
Biotinylated anti-Mouse IgG, BA-9200, Vector Labs). For color development the 
tissue was then treated with 3,3’-Diaminobenzidine tetrahydrochloride (DAB, D5905, 
Sigma-Aldrich) for 5 minutes. Tissue was then immediately washed in 1x TBS and 
mounted on subbed slides. Tissue was allowed to dry overnight on slides before being 
processed through nuclei stain of Cresyl Violet, dehydrations, and coverslipped.  
 
Semi-quantitative Measurement of Immunostaining Quanitification of plaque number 
and size was performed using ImageJ software (NIH, Bethesda, MD, USA). For each 
animal, 5 tissue slices ranging from early hippocampal to late hippocampal tissue 
were measured. Measurements were taken at 2,5X magnification and included the 
entire hippocampal region (CA1, CA2, CA3, and dentate gyrus) as well as the cortex 
areas (including arcuate nucleus, motor cortex, and somatosensory cortex) 
surrounding the hippocampus. Color de-convolution was used to separate the DAB 
stain from the cresyl violet nuclear stain. Images were then transformed to 8-bit gray 
scale images and stain threshold was adjusted to select for visually observed plaque. 
Computer generated number and size of plaque within one frame was reported. 





Western Blot for APP Protein levels were measured on the brain homogenates by 
Western blot analysis. Western blots were performed using a 10% Bis-Tris gel (456-
1046,Bio-Rad, Hercules, CA, USA) and samples were normalized to 25ug protein. 
Briefly, samples were boiled at 95 °C for 15 minutes in the presence of loading buffer 
((25ul) Beta-Mercaptoethanol M6250 Sigma-Aldrich and (475ul) Laemmli Buffer 
161-0737, Bio-Rad), vortexed and spun down before being loaded onto the gel. 
Samples were processed through the gel at 200v for 30 minutes. Gels were then 
transferred to an Immobilon FL PVDF membrane (IPFL00010, Millipore, Billerica, 
MA, USA) using the transblot transfer system (170-4155, Bio-Rad) at 2.5A, 10v for 
10 minutes. Membranes were blocked ((60 min) 927-40000, LiCor, Lincoln, NE, 
USA) before being exposed to primary antibodies against amyloid precursor protein 
(6E10, 39340, Covance, Princeton, NJ, USA) and the housekeeping protein beta-actin 
(4967, Cell Signaling, Danvers, MA, USA) overnight at 4C. Membranes were then 
exposed to secondary anti-mouse (6E10) and anti-rabbit (beta-actin) iRdye antibodies 
(827-08366 and 926-32211, LiCor). Membranes were imaged using the LiCor 
Odyssey system and densitometry performed using the Odyssey software (Licor).  
 
Amyloid Beta ELISA Aβ1-40 and Aβ1-42 variants were quantified using commercially 
available ELISA kit ((40) KHB3481 and (42) KHB3441, Invitrogen, Grand Island, 
NY, USA). Briefly, standards provided by the company, and samples were measured 
using a monoclonal primary (rabbit) antibody specific for the NH2-terminus region of 
Human Aβ 1-40 or 1-42. The bound primary antibody was detected with the use of a 
horseradish peroxidase-labeled anti-rabbit antibody. Finally a stabilized chromagen 
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solution was added which causes a color change directly proportional to the amount of 
Human Aβ present in the sample. Absorbance was measured at 450nm using the 
Victor microplate reader (Wallac 1420, Perkin Elmer, Waltham, MA, USA). Final 
concentration values of Aβ were calculated as pg/mg.  
 
Statistical Analyses  
All statistical analyses were performed using the JMP software program (Version 
10.0, SAS Institute, Inc., Cary, NC, USA).  
Multivariate Analysis Behavioral results were analyzed using a multivariate, 
MANOVA, analysis.  
One-Way ANOVA One-way ANOVA was performed for all analyses. Post-hoc 
analysis was performed using the Tukey Kramer HSD test to compare each treatment 
group to each other (Table 2). 
Table 5.2. Statistical Comparisons were made between groups in each cell by Tukey 
HSD.  
Tukey Test Comparisons 
Biologically Relevant Comparisons 
3xTgAD VEH – 3xTgAD E2 
3xTgAD VEH – 3xTgAD E2Q 
3xTgAD E2 – 3xTgAD E2Q 
 
Results 
Estrogen levels measured by EIA Circulating estradiol levels were measured to 
confirm release of compounds from the osmotic pump (Figure 5.1). We did not 
attempt to quantify the concentration of compound released due to low cross 
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reactivity (<10%) of the estradiol antibody with the quinol compound. Results 
showed that males had low or non-detectable estradiol levels at week 0. Serum was 
collected at 0, 4, and 8 weeks of treatment. The males receiving the vehicle did not 
have detectable levels of estrogen at 0, 4, or 8 weeks of treatment (Figure 5.1). Males 
receiving E2 or E2Q had detectable levels of estrogen at 4 weeks (p < 0.0001) as well 
as 8 weeks of treatment (p < 0.0001) (Figure 5.1). Additionally, while E2 and E2Q 
treated males did not significantly differ from each other at 4 weeks or 8 weeks of 
treatment (Figure 5.1). Females receiving E2 had higher levels of estrogen than 
vehicle treated females at 4 weeks of treatment (p = 0.0004) as well as at 8 weeks of 
treatment (p = 0.0001) (Figure 5.1). Females receiving E2Q had higher levels of 
estrogen than vehicle treated females at 4 weeks of treatment (p < 0.0001) as well as 
at 8 weeks of treatment (p = 0.0011) (Figure 5.1).  
 
Uterine wet weight confirms lack of peripheral tissue stimulation Uterine wet weight 
was measured as gram weight of the uterine tissue to confirm lack of uterine tissue 
stimulation with the E2Q compound (Figure 5.2). There was a significant difference 
(p<0.001) (Figure 5.2) between the vehicle, E2, and E2Q treated groups. E2Q treated 
mice did not show evidence of uterine tissue stimulation.  
 
APP levels decrease in females APP levels in the E2 treated females was decreased in 
compared to both vehicle treated (p = 0.0175) and E2Q treated (p = 0.0010) groups 
(Figure 5.3). There was no statistical difference between the E2 and E2Q treated 
female groups (Figure 5.3). APP levels decreased with E2Q treatment in females but 
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not males (Figure 5.3). No significant differences were observed in the males treated 
with E2 or E2Q compared to vehicle treated males.  
 
Aβ40 and 42 levels are reduced in E2Q treated males Aβ42 levels in E2Q treated 
males significantly decreased (P<0.001) (Figure 5.4) as compared to the vehicle 
treated group. While absolute protein levels were affected, the ratio of 42:40 
remained the same for males.  Female Aβ levels were not affected (Figure 5.4).  
 
Hippocampal and cortex plaque load is not detected Immunohistochemistry for 
measurement of the number of plaques occurring within the hippocampus and cortex 
of 3xTgAD showed plaques were observed at this age (data not shown).  
 
Discussion 
Release and Effects of E2Q A novel compound was tested for efficacy in providing 
neuroprotective effects of estrogen while avoiding adverse peripheral effects 
associated with estrogen. Although the EIA had limited cross reactivity (<10%) with 
the quinol compound, there was sufficient E2Q measured in the plasma samples from 
treated males and females to demonstrate effective release of the compound from the 
minipumps. In the female treated animals uterine tissue was not stimulated by the 
E2Q compound. This confirms previous research (Prokai, personal communication) 
showing little or no stimulation of peripheral steroid sensitive tissues by E2Q. It is 
interesting to see the higher uterine wet weight in our vehicle treated females, which 
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we attribute to their age and the assumption that these mice are in a stage of constant 
estrus.   
Effect of E2Q on APP Our data demonstrated that both the E2 and E2Q treated 
female 3xTgAD animals showed an overall decrease in APP levels measured in brain 
homogenate. In the male 3xTgAD group we did not see a decrease in APP. Our 
female data compliments previous research, which showed that estrogen activation of 
the estrogen receptor (both α and β subtypes) down-regulates the APP gene 
(Manthey and Behl 2006). Based on this previous research, we can speculate that our 
current findings may indeed be a result of a genetic effect, however further studies 
must be performed to determine the accuracy of that hypothesis. Certainly, the 
decrease in APP would be beneficial to an AD patient as a pathway to decrease 
overall Aβ production and subsequent plaque formation.  
Impact on Aβ 40 and 42 As with APP, we saw a decrease of Aβ 40 and 42 with E2 
or E2Q treatment. While it follows that with less APP we would expect less Aβ, we 
cannot confirm if this decrease in Aβ is due to the decrease in APP or a result of 
degradation of the Aβ itself. We know this DTG model begins forming plaques at 12 
months, thus a decrease of Aβ protein at the 12 month time point indicates the quinol 
may be useful as a therapeutic after the onset of AD. Furthermore, the action of the 
Presenilin enzyme regarding APP cleavage and production of Aβ fragments may play 
an important role, especially in this particular 3xTgAD mouse model.  
Aβ Plaque Load in E2Q Treated Mice Plaque was not detected using the 6E10 
staining in our 3xTgAD mice. It has been shown in a previous data (Duffy, personal 
communication) that our 3xTgAD does not show detectable levels of plaque within 
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the hippocampus at the 12 -14 month age. Other regions of brain tissue should be 
examined to determine any changes in other areas such as the subbiculum, which do 
show plaques at the 12-14 month age (Duffy, personal communication). 
 In summary, the E2 and E2Q treatment groups appeared to be beneficial based 
on biochemical changes in the 3xTgAD mouse. The greatest benefit of E2Q 
compared to E2 is the lack of uterine tissue stimulation very clearly seen in our study. 
We also observed a marked decrease in APP and Aβ protein levels, which may 
benefit AD patients. Due to the age of pathology onset of this transgenic line, further 
studies are critical to determine overarching effects of E2Q. The positive effects of 
E2Q, combined with effectiveness similar to that of the E2, makes this compound 
































Chapter 6:  Concluding Remarks 
Concluding Remarks 
 The beneficial effects of estrogens are often over shadowed by their negative 
peripheral effects (Resnick 1997; Rossouw 2002). Here we show the quinol 
compound provides a benefit at both the cognitive and molecular level, but does not 
stimulate uterine tissue like estradiol (E2).  
	   In	  the	  first	  study	  we	  assessed	  the	  proper	  delivery	  of	  the	  estradiol-­‐
quinol	   (E2Q).	   The	   estradiol	   EIA	   we	   used	   recognized	   the	   E2Q	   in	   the	   treated	  
animals	  enabling	  us	  to	  confirm	  appropriate	  delivery	  of	  the	  compound.	  However,	  
there	  was	  no	  stimulation	  of	  the	  uterine	  tissue,	  which	  is	  an	  important	  component	  
of	   these	   studies.	   This	   lack	   of	   uterine	   stimulation	  will	   allow	   E2Q	   to	   be	   used	   in	  
situations	  where	  estrogen	  sensitive	  tissue	  stimulation	  is	  a	  concern.	  We	  also	  saw	  
a	   decrease	   in	   errors	   performed	   by	   both	   intact	   and	   OVX	   females	   of	   the	   E2Q	  
treatment	  group.	  These	  data	  demonstrate	  that	  E2Q	  is	  beneficial	  at	  ameliorating	  
the	   cognitive	   deficits	   seen	   in	   the	   DTG	   AD	   mouse	   model.	   Additionally,	   overall	  
levels	  of	  APP	  and	  Aβ were	  decreased	  in	  the	  E2	  and	  E2Q	  treated	  animals.	  These 
data compliment previous research, which showed that estrogen activation of the 
estrogen receptor (both α and β subtypes) down-regulates the APP gene (Manthey 
and Behl 2006). Based on this previous research, we can speculate that our current 
findings may be a result of a gene level effect, however further studies must be 
performed to determine the accuracy of that hypothesis. In general though, a decrease 
in APP and Aβ protein level would be beneficial to an AD patient as a pathway to 
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decrease overall Aβ production and subsequent plaque formation. Our data did not 
show a significant difference in the overall plaque load. This may be due to the fact 
that E2Q is not able to degrade plaques already formed, and instead may decrease 
further production of plaque by impacting levels of the APP and Aβ proteins.  
 In the second study, we focused on electron transport chain complexes, lipid 
peroxidation, and antioxidant activity. Estradiol levels were the same as in the first 
study, including the lack of uterine tissue stimulation. Our data showed there was an 
increase of protein complex IV in the OVX E2 and E2Q treated females, which could 
be extremely beneficial in regards to humans with AD since decreased complex IV 
protein levels have been demonstrated in the AD population (Cardoso 2004). 
Additionally, the increase of protein complex IV in the OVX AD system is a positive 
result since this shows us the OVX insult can be overcome in some aspects with the 
E2 or E2Q treatments. We also saw an increase of protein complexes II and III, which 
could also be beneficial in overall cell viability by increasing the cell’s capacity to 
perform oxidative phosphorylation. Additionally we examined superoxide dismutase 
(SOD) activity levels and found DTG OVX females showed significantly lower SOD 
levels in the vehicle and E2 treatment groups as compared to the NTG OVX E2 
treatment groups. These data indicate there are initial differences in the DTG OVX 
groups and regardless of treatment SOD activity levels were not increased by E2 or 
E2Q. Similarly lipid peroxidation, which is a measure of MDA formation relating to 
overall reactive oxygen species (ROS) increased in the NTG E2Q OVX group (Table 
6.1). This response could be due to a lack of endogenous estrogens. Since the E2Q 
would primarily affect the brain, the lack of circulating estrogen could leave the 
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peripheral system vulnerable to increased ROS. Differential effects of E2 and E2Q are 
shown in table 6.1.  
 In all treatment groups we saw the proper delivery of each compound 
including vehicle, E2, and E2Q. The estradiol EIA we used recognized the E2Q in the 
treated animals and thus we were able to confirm delivery of the compound. One of 
the most important findings was that uterine wet weight was not stimulated by E2Q. 
All OVX females treated with E2Q had low uterine wet weights, similar to those of 
the vehicle treated females, indicating that E2Q did not stimulate the uterine tissue as 
was seen with E2 treatment. In the E2Q treated 3xTgAD females, uterine wet weights 
were actually lower than vehicle treated females. This is an interesting finding and 
one reason for this difference between the DTG and 3xTgAD findings may be the age 
of the 3xTgAD (Table 6.2) females (12 months) at treatment.  
 In the behavioral testing we saw a cognitive benefit in vehicle treated DTG 
animals compared to the E2Q treated animals for intact, OVX, and male groups. All 
three groups made fewer errors in the E2Q treated DTG groups on the third day of 
testing as compared to the vehicle treated DTG controls. This benefit was seen across 
all three treatment paradigms and indicates the strong benefit of E2Q in both males 
and females.  
 Overall total APP protein level was altered in all treatment groups (DTG and 
3xTgAD) except in the OVX DTG females. This decrease in APP levels is consistent 
with previous research, which showed estrogen activation of estrogen receptors 
decreased APP gene levels (Manthey and Behl 2006). However, this decrease was not 
observed in the OVX treated females in any treatment groups. It is possible the 
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surgical OVX procedure was stressful. The osmotic pump insertion was performed 
immediately following OVX and established circulating E2 levels similar to intact 
females. Therefore, we would expect the E2 treated animals to look similar to the 
vehicle treated intact females, however, this is not the case. These results indicate that 
OVX may have additional effects. At this point, the reason or their difference is 
unclear.  
 Amyloid-beta (Aβ) levels were decreased with E2 and E2Q and it logically 
follows that there would be lower APP levels. However, other mechanism may be 
involved here because there were decreased Aβ levels in the OVX treated females, 
without decreased APP levels. Possibilities include the alteration of presenilin activity 
due to the estrogen treatments, or a change in neprilysin levels as a result of the 
estrogen treatments. Neprilysin acts on Aβ and would not have effects on APP levels.  
 Overall, positive changes were observed in behavioral responses, decreases in 
APP protein level and Aβ levels with E2Q. These changes combined with the lack of 
uterine tissue stimulation make E2Q unique in that it combines the positive benefits 
of estradiol without the negative peripheral characteristics of stimulation of estrogen 
sensitive tissues. Further studies should aim at determining optimal dose and 
treatment period. Additionally, the role of the presenilin enzymes and tau protein in 
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